BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558-562. [PMID: 25428503 DOI: 10.1038/nature13904] [Cited by in Crossref: 1564] [Cited by in F6Publishing: 1486] [Article Influence: 223.4] [Reference Citation Analysis]
Number Citing Articles
1 Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ, Ji J. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res 2020;8:35. [PMID: 32864132 DOI: 10.1186/s40364-020-00212-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
2 Friedrich J, Heim L, Trufa DI, Sirbu H, Rieker RJ, Chiriac MT, Finotto S. STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFα mediated immune responses in a model of NSCLC. Oncotarget 2018;9:37157-72. [PMID: 30647851 DOI: 10.18632/oncotarget.26441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
3 Sjödahl G, Jackson CL, Bartlett JM, Siemens DR, Berman DM. Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. J Pathol 2019;247:563-73. [PMID: 30604486 DOI: 10.1002/path.5230] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
4 Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, Endo I, Nakatsura T. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology. 2017;6:e1346764. [PMID: 29123959 DOI: 10.1080/2162402x.2017.1346764] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
5 Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681-700. [PMID: 26484443 DOI: 10.1038/nrgastro.2015.173] [Cited by in Crossref: 252] [Cited by in F6Publishing: 262] [Article Influence: 36.0] [Reference Citation Analysis]
6 Desai NB, Laine AM, Timmerman RD. Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.Br J Radiol. 2017;90:20160500. [PMID: 28008774 DOI: 10.1259/bjr.20160500] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
7 Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 2015;26:1824-9. [PMID: 25888611 DOI: 10.1093/annonc/mdv182] [Cited by in Crossref: 128] [Cited by in F6Publishing: 121] [Article Influence: 18.3] [Reference Citation Analysis]
8 Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74-80. [PMID: 25838376 DOI: 10.1126/science.aaa6204] [Cited by in Crossref: 939] [Cited by in F6Publishing: 879] [Article Influence: 134.1] [Reference Citation Analysis]
9 Kersten K, Salvagno C, de Visser KE. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol 2015;6:516. [PMID: 26500653 DOI: 10.3389/fimmu.2015.00516] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
10 Jia W, Gao Q, Han A, Zhu H, Yu J. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16:655-670. [PMID: 31908886 DOI: 10.20892/j.issn.2095-3941.2019.0144] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
11 Anderson B. Bladder cancer: overview and management. Part 2: muscle-invasive and metastatic bladder cancer. Br J Nurs 2018;27:S8-S20. [DOI: 10.12968/bjon.2018.27.18.s8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Sundararajan S, Vogelzang NJ. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon? Future Oncology 2015;11:2299-306. [DOI: 10.2217/fon.15.162] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
13 Majzner RG, Heitzeneder S, Mackall CL. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. Cancer Cell 2017;31:476-85. [PMID: 28366678 DOI: 10.1016/j.ccell.2017.03.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 14.8] [Reference Citation Analysis]
14 Gu Y, Zhang H, Liu Z, Xia Y, Liang B, Liang L. Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. Asia Pac J Clin Oncol 2020;16:e160-78. [PMID: 32779383 DOI: 10.1111/ajco.13385] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945-950. [PMID: 25981182 DOI: 10.1111/cas.12695] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
16 Netto GJ. Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. The Lancet 2016;387:1881-2. [DOI: 10.1016/s0140-6736(16)00654-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
17 Hamilton DH, David JM, Dominguez C, Palena C. Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. Cells Tissues Organs 2017;203:128-38. [PMID: 28214895 DOI: 10.1159/000446495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
18 Sartore-bianchi A, Loupakis F, Argilés G, Prager G. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology 2016;27:1456-66. [DOI: 10.1093/annonc/mdw191] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
19 Rahimi Kalateh Shah Mohammad G, Ghahremanloo A, Soltani A, Fathi E, Hashemy SI. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. J Cell Physiol 2020;235:5449-60. [PMID: 31970790 DOI: 10.1002/jcp.29491] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
20 Qian J, Chen T, Wu Q, Zhou L, Zhou W, Wu L, Wang S, Lu J, Wang W, Li D, Xie H, Su R, Guo D, Liu Z, He N, Yin S, Zheng S. Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8+ T cells in liver cancer. Cancer Lett 2020;495:1-11. [PMID: 32949680 DOI: 10.1016/j.canlet.2020.09.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Lehrke HD, Graham RP, McWilliams RR, Lam-Himlin DM, Smyrk TC, Jenkins S, Dong H, Zhang L. Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. Am J Clin Pathol. 2017;148:441-449. [PMID: 29069274 DOI: 10.1093/ajcp/aqx092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
22 Zhao Y, Lee CK, Lin CH, Gassen RB, Xu X, Huang Z, Xiao C, Bonorino C, Lu LF, Bui JD, Hui E. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity 2019;51:1059-1073.e9. [PMID: 31757674 DOI: 10.1016/j.immuni.2019.11.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 23.7] [Reference Citation Analysis]
23 Ciccarese C, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Conti A, Tortora G, Cascinu S, Montironi R. Present and future of personalized medicine in adult genitourinary tumors. Future Oncol 2015;11:1381-8. [PMID: 25952784 DOI: 10.2217/fon.15.30] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
24 Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7. [PMID: 30774998 DOI: 10.1038/s41541-019-0103-y] [Cited by in Crossref: 195] [Cited by in F6Publishing: 173] [Article Influence: 65.0] [Reference Citation Analysis]
25 Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, Guo J, Peng H, Chen M, Fu YX, Tang H. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun 2020;11:4835. [PMID: 32973173 DOI: 10.1038/s41467-020-18570-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 21.5] [Reference Citation Analysis]
26 Cheyuo C, Radwan W, Ahn J, Gyure K, Qaiser R, Tomboc P. Biallelic PMS2 Mutation and Heterozygous DICER1 Mutation Presenting as Constitutional Mismatch Repair Deficiency With Corpus Callosum Agenesis: Case Report and Review of Literature. J Pediatr Hematol Oncol 2017;39:e381-7. [PMID: 28562508 DOI: 10.1097/MPH.0000000000000863] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Kochin V, Kanaseki T, Tokita S, Miyamoto S, Shionoya Y, Kikuchi Y, Morooka D, Hirohashi Y, Tsukahara T, Watanabe K, Toji S, Kokai Y, Sato N, Torigoe T. HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. Oncoimmunology 2017;6:e1293214. [PMID: 28533942 DOI: 10.1080/2162402X.2017.1293214] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
28 Mo M, Hu X, He W, Zu X, Wang L, Li Y. Identification of key genes and microRNA regulatory network in development and progression of urothelial bladder carcinoma. Transl Androl Urol 2021;10:438-47. [PMID: 33532331 DOI: 10.21037/tau-20-1124] [Reference Citation Analysis]
29 Mondanelli G, Volpi C, Orabona C, Grohmann U. Challenges in the design of reliable immuno-oncology mouse models to inform drug development. Future Medicinal Chemistry 2017;9:1313-7. [DOI: 10.4155/fmc-2017-0027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
30 Zavala VA, Kalergis AM. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015;145:182-201. [PMID: 25826229 DOI: 10.1111/imm.12459] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
31 Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy 2015;7:777-92. [PMID: 26250412 DOI: 10.2217/imt.15.49] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
32 Liu SL, Bian LJ, Liu ZX, Chen QY, Sun XS, Sun R, Luo DH, Li XY, Xiao BB, Yan JJ, Lu ZJ, Yan SM, Yuan L, Tang LQ, Li JM, Mai HQ. Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. J Immunother Cancer 2020;8:e000205. [PMID: 32303611 DOI: 10.1136/jitc-2019-000205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
33 Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med 2015;12:201-8. [PMID: 26487965 DOI: 10.7497/j.issn.2095-3941.2015.0046] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
34 Marcucci F, Rumio C, Corti A. Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness. Biochim Biophys Acta Rev Cancer 2017;1868:571-83. [PMID: 29056539 DOI: 10.1016/j.bbcan.2017.10.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
35 Reisz PA, Laviana AA, Chang SS. Management of High-grade T1 Urothelial Carcinoma. Curr Urol Rep 2018;19:103. [PMID: 30367268 DOI: 10.1007/s11934-018-0850-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Bellmunt J. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol 2016;69:634-41. [PMID: 26264159 DOI: 10.1016/j.eururo.2015.07.042] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
37 Thibault C, Gross-goupil M. Innovations dans les traitements systémiques du carcinome urothélial infiltrant. Bulletin du Cancer 2020;107:S6-S16. [DOI: 10.1016/s0007-4551(20)30273-3] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, Netto G, Bivalacqua TJ. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology 2016;5:e1134412. [PMID: 27467953 DOI: 10.1080/2162402X.2015.1134412] [Cited by in Crossref: 79] [Cited by in F6Publishing: 52] [Article Influence: 13.2] [Reference Citation Analysis]
39 Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 2015;67:4-17. [PMID: 25749122 DOI: 10.1016/j.molimm.2015.02.009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 134] [Article Influence: 18.9] [Reference Citation Analysis]
40 Richards RM, Sotillo E, Majzner RG. CAR T Cell Therapy for Neuroblastoma. Front Immunol 2018;9:2380. [PMID: 30459759 DOI: 10.3389/fimmu.2018.02380] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
41 Bockorny B, Pectasides E. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. Future Oncol. 2016;12:1833-1846. [PMID: 27166503 DOI: 10.2217/fon-2016-0103] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
42 Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat Rev 2017;53:79-97. [PMID: 28088073 DOI: 10.1016/j.ctrv.2016.12.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
43 Roudko V, Greenbaum B, Bhardwaj N. Computational Prediction and Validation of Tumor-Associated Neoantigens. Front Immunol 2020;11:27. [PMID: 32117226 DOI: 10.3389/fimmu.2020.00027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
44 Denton AE, Roberts EW, Fearon DT. Stromal Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2018;1060:99-114. [PMID: 30155624 DOI: 10.1007/978-3-319-78127-3_6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 16.7] [Reference Citation Analysis]
45 Prado K, Zhang KX, Pellegrini M, Chin AI. Sequencing of cancer cell subpopulations identifies micrometastases in a bladder cancer patient. Oncotarget 2017;8:45619-25. [PMID: 28487492 DOI: 10.18632/oncotarget.17312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
46 Sridhar SS. Evolving Treatment of Advanced Urothelial Cancer. JOP 2017;13:309-15. [DOI: 10.1200/jop.2017.022137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
47 Lu LC, Lee YH, Chang CJ, Shun CT, Fang CY, Shao YY, Liu TH, Cheng AL, Hsu CH. Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer. 2019;8:110-120. [PMID: 31019901 DOI: 10.1159/000489021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
48 Guo W, Wang P, Li N, Shao F, Zhang H, Yang Z, Li R, Gao Y, He J. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget 2018;9:13920-33. [PMID: 29568405 DOI: 10.18632/oncotarget.23810] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
49 Zhang N, Dou Y, Liu L, Zhang X, Liu X, Zeng Q, Liu Y, Yin M, Liu X, Deng H, Song D. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine 2019;40:151-62. [PMID: 30711516 DOI: 10.1016/j.ebiom.2019.01.054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
50 Zhang J, Wolfgang CL, Zheng L. Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel). 2018;10. [PMID: 29385739 DOI: 10.3390/cancers10020039] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
51 Liu L, Hu J, Wang Y, Sun T, Zhou X, Li X, Ma F. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis. Aging (Albany NY) 2020;12:11967-89. [PMID: 32570217 DOI: 10.18632/aging.103364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses 2015;7:5889-901. [PMID: 26580645 DOI: 10.3390/v7112914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
53 Hao YN, Zhang WX, Gao YR, Wei YN, Shu Y, Wang JH. State-of-the-art advances of copper-based nanostructures in the enhancement of chemodynamic therapy. J Mater Chem B 2021;9:250-66. [PMID: 33237121 DOI: 10.1039/d0tb02360d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 5.5] [Reference Citation Analysis]
54 Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G. Correlation between messenger RNA expression and protein expression of immune checkpoint–associated molecules in bladder urothelial carcinoma: A retrospective study. Urologic Oncology: Seminars and Original Investigations 2017;35:257-63. [DOI: 10.1016/j.urolonc.2017.01.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
55 Kim D, Choi Y, Ireland J, Foreman O, Tam RN, Patel R, Schleifman EB, Motlhabi M, French D, Wong CV, Peters E, Molinero L, Raja R, Amler LC, Hampton GM, Lackner MR, Kabbarah O. Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers. PLoS One 2016;11:e0165856. [PMID: 27846280 DOI: 10.1371/journal.pone.0165856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, Di Lorenzo G, Bellmunt J. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol 2016;195:277-82. [PMID: 26292040 DOI: 10.1016/j.juro.2015.07.111] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
57 Medina PJ, Adams VR. PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy 2016;36:317-34. [PMID: 26822752 DOI: 10.1002/phar.1714] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
58 Glaser AP, Fantini D, Shilatifard A, Schaeffer EM, Meeks JJ. The evolving genomic landscape of urothelial carcinoma. Nat Rev Urol 2017;14:215-29. [DOI: 10.1038/nrurol.2017.11] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 10.4] [Reference Citation Analysis]
59 You W, Shang B, Sun J, Liu X, Su L, Jiang S. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep 2020;44:424-37. [PMID: 32627031 DOI: 10.3892/or.2020.7643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
60 Fisher MD, Shenolikar R, Miller PJ, Fenton M, Walker MS. Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015. Clin Genitourin Cancer. 2018;16:e1171-e1179. [PMID: 30206026 DOI: 10.1016/j.clgc.2018.07.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
61 Raggi D, Giannatempo P, Marandino L, Pierantoni F, Maruzzo M, Lipari H, Banna GL, De Giorgi U, Casadei C, Naglieri E, Buti S, Bersanelli M, Stellato M, Santini D, Vignani F, Roviello G, Veccia A, Caffo O, Losanno T, Calabrò F, Mucciarini C, Pignata S, Necchi A, Maio MD; MEET-URO Group. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study. Clin Genitourin Cancer 2021:S1558-7673(21)00238-X. [PMID: 35000876 DOI: 10.1016/j.clgc.2021.12.008] [Reference Citation Analysis]
62 Irving M, Vuillefroy de Silly R, Scholten K, Dilek N, Coukos G. Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol 2017;8:267. [PMID: 28421069 DOI: 10.3389/fimmu.2017.00267] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
63 Gerace C, Montorsi F, Tambaro R, Cartenì G, De Luca S, Tucci M, Martorana G, Basso U, Cardosi L, Teruzzi C. Cost of illness of urothelial bladder cancer in Italy. Clinicoecon Outcomes Res 2017;9:433-42. [PMID: 28769578 DOI: 10.2147/CEOR.S135065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
64 Ma Q, Li S, Li X, Zhou T, Zhao Y, Liu F, Yu X, Lin J, Chen F, Cao J, Xi H, Li H. Long non-coding RNA DILC suppresses bladder cancer cells progression. Gene 2019;710:193-201. [DOI: 10.1016/j.gene.2019.06.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
65 Jiang DM, Sridhar SS. Prime time for immunotherapy in advanced urothelial cancer. Asia-Pac J Clin Oncol 2018;14:24-32. [DOI: 10.1111/ajco.13059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
66 Seifert L, Miller G. Molecular Pathways: The Necrosome-A Target for Cancer Therapy. Clin Cancer Res 2017;23:1132-6. [PMID: 27932417 DOI: 10.1158/1078-0432.CCR-16-0968] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
67 Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016; 22(2): 557-566 [PMID: 26811607 DOI: 10.3748/wjg.v22.i2.557] [Cited by in CrossRef: 154] [Cited by in F6Publishing: 138] [Article Influence: 25.7] [Reference Citation Analysis]
68 Suzuki S, Ishida T, Yoshikawa K, Ueda R. Current status of immunotherapy. Jpn J Clin Oncol 2016;46:191-203. [PMID: 26819277 DOI: 10.1093/jjco/hyv201] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
69 Sweis RF, Galsky MD. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol 2016;34:556-65. [PMID: 27836246 DOI: 10.1016/j.urolonc.2016.10.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
70 Mahe M, Dufour F, Neyret-Kahn H, Moreno-Vega A, Beraud C, Shi M, Hamaidi I, Sanchez-Quiles V, Krucker C, Dorland-Galliot M, Chapeaublanc E, Nicolle R, Lang H, Pouponnot C, Massfelder T, Radvanyi F, Bernard-Pierrot I. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med 2018;10:e8163. [PMID: 29463565 DOI: 10.15252/emmm.201708163] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
71 Vandeven N, Nghiem P. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy 2016;8:907-21. [PMID: 27381685 DOI: 10.2217/imt-2016-0009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
72 Tshuma N, Glynn N, Evanson J, Powles T, Drake W. Hypothalamitis and severe hypothalamic dysfunction associated with anti–programmed cell death ligand 1 antibody treatment. European Journal of Cancer 2018;104:247-9. [DOI: 10.1016/j.ejca.2018.09.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
73 Lin S, Huang G, Cheng L, Li Z, Xiao Y, Deng Q, Jiang Y, Li B, Lin S, Wang S, Wu Q, Yao H, Cao S, Li Y, Liu P, Wei W, Pei D, Yao Y, Wen Z, Zhang X, Wu Y, Zhang Z, Cui S, Sun X, Qian X, Li P. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs 2018;10:1301-11. [PMID: 30204048 DOI: 10.1080/19420862.2018.1518948] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
74 Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother 2016;12:2777-89. [PMID: 27398650 DOI: 10.1080/21645515.2016.1199310] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
75 London NR Jr, Rooper LM, Bishop JA, Xu H, Bernhardt LJ, Ishii M, Hann CL, Taube JM, Izumchenko E, Gaykalova DA, Gallia GL. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. World Neurosurg 2020;135:e187-93. [PMID: 31785431 DOI: 10.1016/j.wneu.2019.11.112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
76 Penaloza-MacMaster P. CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. Immunology 2017;151:146-53. [PMID: 28375543 DOI: 10.1111/imm.12739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
77 Powles T, Smith K, Stenzl A, Bedke J. Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology 2017;72:477-81. [DOI: 10.1016/j.eururo.2017.03.047] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
78 Pfannenstiel LW, McNeilly C, Xiang C, Kang K, Diaz-Montero CM, Yu JS, Gastman BR. Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. Oncoimmunology 2019;8:e1507669. [PMID: 30546944 DOI: 10.1080/2162402X.2018.1507669] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
79 Powles T, Walker J, Andrew Williams J, Bellmunt J. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treatment Reviews 2020;82:101925. [DOI: 10.1016/j.ctrv.2019.101925] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
80 Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol 2017;28:1988-95. [PMID: 28595336 DOI: 10.1093/annonc/mdx190] [Cited by in Crossref: 151] [Cited by in F6Publishing: 147] [Article Influence: 37.8] [Reference Citation Analysis]
81 Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015;125:3393-400. [PMID: 25833961 DOI: 10.1182/blood-2015-02-567453] [Cited by in Crossref: 157] [Cited by in F6Publishing: 153] [Article Influence: 22.4] [Reference Citation Analysis]
82 Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, Bellmunt J, Necchi A. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 2016;27:49-61. [PMID: 26487582 DOI: 10.1093/annonc/mdv509] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 9.4] [Reference Citation Analysis]
83 Rouanne M, Loriot Y, Lebret T, Soria J. Novel therapeutic targets in advanced urothelial carcinoma. Critical Reviews in Oncology/Hematology 2016;98:106-15. [DOI: 10.1016/j.critrevonc.2015.10.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
84 Ratner M. Genentech's PD-L1 agent approved for bladder cancer. Nat Biotechnol 2016;34:789-90. [DOI: 10.1038/nbt0816-789] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ratta R, Zappasodi R, Raggi D, Grassi P, Verzoni E, Necchi A, Di Nicola M, Salvioni R, de Braud F, Procopio G. Immunotherapy advances in uro-genital malignancies. Crit Rev Oncol Hematol 2016;105:52-64. [PMID: 27372200 DOI: 10.1016/j.critrevonc.2016.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
86 Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, Walker E, Hegde PS, Williams JA, Koeppen H, Boyd Z. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Appl Immunohistochem Mol Morphol 2019;27:92-100. [PMID: 29346180 DOI: 10.1097/PAI.0000000000000594] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 35.0] [Reference Citation Analysis]
87 Mullane SA, Bellmunt J. Cancer immunotherapy: new applications in urologic oncology. Curr Opin Urol 2016;26:556-63. [PMID: 27584023 DOI: 10.1097/MOU.0000000000000337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
88 Jokisch JF, Karl A, Stief C. Intravesical immunotherapy in nonmuscle invasive bladder cancer. Indian J Urol 2015;31:304-11. [PMID: 26604441 DOI: 10.4103/0970-1591.166452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
89 Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018;6:4. [PMID: 29368638 DOI: 10.1186/s40425-018-0314-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 18.8] [Reference Citation Analysis]
90 Bidnur S, Savdie R, Black PC. Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer 2016;2:15-25. [PMID: 27376121 DOI: 10.3233/BLC-150026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
91 Zhang T, Harrison MR, O'Donnell PH, Alva AS, Hahn NM, Appleman LJ, Cetnar J, Burke JM, Fleming MT, Milowsky MI, Mortazavi A, Shore N, Sonpavde GP, Schmidt EV, Bitman B, Munugalavadla V, Izumi R, Patel P, Staats J, Chan C, Weinhold KJ, George DJ. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer 2020;126:4485-97. [PMID: 32757302 DOI: 10.1002/cncr.33067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
92 Schmitt AM, Dumas L, Larkin J. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. Expert Rev Anticancer Ther 2022;:1-9. [PMID: 34904502 DOI: 10.1080/14737140.2022.2017286] [Reference Citation Analysis]
93 Feucht J, Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016;7:76902-19. [PMID: 27708227 DOI: 10.18632/oncotarget.12357] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 19.8] [Reference Citation Analysis]
94 Trono P, Sistigu A, Palermo B, Ciliberto G, Nisticò P. Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerg Top Life Sci 2017;1:471-86. [PMID: 33525801 DOI: 10.1042/ETLS20170068] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
95 Li DR, Zhang H, Peek E, Wang S, Du L, Li G, Chin AI. Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer. J Urol 2015;194:547-55. [PMID: 25748177 DOI: 10.1016/j.juro.2015.02.2918] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
96 McConkey DJ, Choi W, Dinney CP. Genetic subtypes of invasive bladder cancer. Curr Opin Urol 2015;25:449-58. [PMID: 26218634 DOI: 10.1097/MOU.0000000000000200] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
97 Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-5039. [PMID: 27574444 DOI: 10.2147/ott.s105862] [Cited by in Crossref: 297] [Cited by in F6Publishing: 192] [Article Influence: 49.5] [Reference Citation Analysis]
98 Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, von Bergwelt-Baildon M, Kreipe H, Reddy S, Christgen M, Zippelius A. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med 2015;7:315ra188. [PMID: 26606967 DOI: 10.1126/scitranslmed.aac4925] [Cited by in Crossref: 148] [Cited by in F6Publishing: 128] [Article Influence: 24.7] [Reference Citation Analysis]
99 Karachi A, Yang C, Dastmalchi F, Sayour EJ, Huang J, Azari H, Long Y, Flores C, Mitchell DA, Rahman M. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol 2019;21:730-41. [PMID: 30668768 DOI: 10.1093/neuonc/noz015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
100 Qiao B, Huang J, Mei Z, Lam AK, Zhao J, Ying L. Analysis of Immune Microenvironment by Multiplex Immunohistochemistry Staining in Different Oral Diseases and Oral Squamous Cell Carcinoma. Front Oncol 2020;10:555757. [PMID: 33364188 DOI: 10.3389/fonc.2020.555757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
101 Noskova H, Kyr M, Pal K, Merta T, Mudry P, Polaskova K, Ivkovic TC, Adamcova S, Hornakova T, Jezova M, Kren L, Sterba J, Slaby O. Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision? Cancers (Basel) 2020;12:E230. [PMID: 31963488 DOI: 10.3390/cancers12010230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
102 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
103 Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, Xu J, Fan T, Sun X, Yang R, Wang J, Yao Y, Xu G, Yan X, Wang T, Liang H, Zen K. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biol 2021;22:104. [PMID: 33849634 DOI: 10.1186/s13059-021-02331-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Michalarea V, Fontana E, Garces AI, Williams A, Smyth EC, Picchia S, Rao S, Chau I, Cunningham D, Bali MA. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Curr Probl Cancer 2019;43:487-94. [PMID: 30827742 DOI: 10.1016/j.currproblcancer.2019.01.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
105 Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11. [PMID: 25901283 DOI: 10.1186/s40425-015-0057-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 174] [Article Influence: 26.3] [Reference Citation Analysis]
106 Bayraktar R, Van Roosbroeck K. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer Metastasis Rev 2018;37:33-44. [PMID: 29282605 DOI: 10.1007/s10555-017-9724-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 21.0] [Reference Citation Analysis]
107 Gompertz-Mattar M, Perales J, Sahu A, Mondaca S, Gonzalez S, Uribe P, Navarrete-Dechent C. Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. Arch Dermatol Res 2021. [PMID: 34647186 DOI: 10.1007/s00403-021-02289-w] [Reference Citation Analysis]
108 Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol 2016;34:1500-9. [PMID: 26926681 DOI: 10.1200/JCO.2015.65.0218] [Cited by in Crossref: 58] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
109 Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol. 2016;27:214-224. [PMID: 26578728 DOI: 10.1093/annonc/mdv550] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 9.1] [Reference Citation Analysis]
110 Kandalaft LE, Harari A. Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. Cancers (Basel) 2021;13:5819. [PMID: 34830973 DOI: 10.3390/cancers13225819] [Reference Citation Analysis]
111 Wang Y, Guo H, Feng Z, Wang S, Wang Y, He Q, Li G, Lin W, Xie XQ, Lin Z. PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance. Molecules 2019;24:E3784. [PMID: 31640203 DOI: 10.3390/molecules24203784] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
112 Hiniker SM, Maecker HT, Knox SJ. Predictors of clinical response to immunotherapy with or without radiotherapy. J Radiat Oncol. 2015;4:339-345. [PMID: 26709361 DOI: 10.1007/s13566-015-0219-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
113 Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B, Luciani A, Tournigand C, Cherqui D, Azoulay D, Pawlotsky JM, Calderaro J. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 2017;8:24644-51. [PMID: 28445951 DOI: 10.18632/oncotarget.15602] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 19.5] [Reference Citation Analysis]
114 Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492-1504. [PMID: 27207108 DOI: 10.1093/annonc/mdw217] [Cited by in Crossref: 219] [Cited by in F6Publishing: 211] [Article Influence: 36.5] [Reference Citation Analysis]
115 Yamashita H, Amponsa VO, Warrick JI, Zheng Z, Clark PE, Raman JD, Wu XR, Mendelsohn C, DeGraff DJ. On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nat Rev Urol 2017;14:98-106. [PMID: 27898096 DOI: 10.1038/nrurol.2016.239] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
116 Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 2018;128:805-15. [PMID: 29337305 DOI: 10.1172/JCI96113] [Cited by in Crossref: 207] [Cited by in F6Publishing: 147] [Article Influence: 51.8] [Reference Citation Analysis]
117 Bellmunt J, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. EJC Suppl 2016;14:1-20. [PMID: 27358584 DOI: 10.1016/j.ejcsup.2016.01.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
118 Nykopp TK, Batista da Costa J, Mannas M, Black PC. Current Clinical Trials in Non-muscle Invasive Bladder Cancer. Curr Urol Rep 2018;19:101. [PMID: 30357541 DOI: 10.1007/s11934-018-0852-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
119 Rhea LP, Aragon-Ching JB. Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. Clin Med Insights Oncol 2021;15:11795549211044963. [PMID: 34602833 DOI: 10.1177/11795549211044963] [Reference Citation Analysis]
120 Platten M, Bunse L, Wick W, Bunse T. Concepts in glioma immunotherapy. Cancer Immunol Immunother 2016;65:1269-75. [DOI: 10.1007/s00262-016-1874-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
121 Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, Papazoglou D, Sutton LA, Rosenquist R, Amini RM, Chiu H, Lopez-Girona A, Janardhanan P, Awan FT, Jones J, Kay NE, Shanafelt TD, Tallman MS, Stamatopoulos K, Patten PEM, Vardi A, Ramsay AG. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood 2021;137:216-31. [PMID: 33024998 DOI: 10.1182/blood.2020006073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
122 Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, Buckley R, Persad R, Palou J, Soloway M, Witjes JA. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol 2017;14:244-55. [DOI: 10.1038/nrurol.2017.16] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 11.2] [Reference Citation Analysis]
123 Rink M. The landscape of genetics and biomarkers in bladder cancer. Transl Androl Urol 2017;6:1027-30. [PMID: 29354489 DOI: 10.21037/tau.2017.11.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
124 Wang S, Guan G, Zou C, Guo Q, Cheng W, Shen S, Dong F, Wu A, Li G, Zhu C. Genome profiling of mismatch repair genes in eight types of tumors. Cell Cycle 2021;20:1091-106. [PMID: 33966609 DOI: 10.1080/15384101.2021.1922160] [Reference Citation Analysis]
125 Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol 2017;12:125-38. [PMID: 27995439 DOI: 10.1007/s11523-016-0471-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
126 Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 2018;9:10284-93. [PMID: 29535806 DOI: 10.18632/oncotarget.22888] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
127 Kim DK, Lee JY, Jung JH, Hah YS, Cho KS. Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials. Investig Clin Urol 2019;60:64-74. [PMID: 30838338 DOI: 10.4111/icu.2019.60.2.64] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
128 Li Q, Quan L, Lyu J, He Z, Wang X, Meng J, Zhao Z, Zhu L, Liu X, Li H. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget 2016;7:64967-76. [PMID: 27533458 DOI: 10.18632/oncotarget.11274] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
129 Wang M, Ma X, Guo L, Xia F. Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Des Devel Ther 2017;11:2851-60. [PMID: 29033546 DOI: 10.2147/DDDT.S146286] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
130 Hu X, Wu T, Bao Y, Zhang Z. Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. J Control Release 2017;256:26-45. [PMID: 28434891 DOI: 10.1016/j.jconrel.2017.04.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
131 Bao Y, Liu X, Liu Y, Wang S, Wu B. Ras-association domain family 1 (RASSF1A) gene regulates progression, migration and invasion of bladder cancer. Surgical Oncology 2019;30:63-71. [DOI: 10.1016/j.suronc.2019.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
132 Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022;15:6. [PMID: 35033167 DOI: 10.1186/s13045-021-01182-3] [Reference Citation Analysis]
133 Chakravarty D, Huang L, Kahn M, Tewari AK. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. Urol Clin North Am 2020;47:487-510. [PMID: 33008499 DOI: 10.1016/j.ucl.2020.07.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
134 van den Bulk J, Verdegaal EM, de Miranda NF. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol. 2018;8. [PMID: 29875199 DOI: 10.1098/rsob.180037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis]
135 Yuen C, Reid P, Zhang Z, Soliven B, Luke JJ, Rezania K. Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study. Journal of Immunotherapy 2019;42:94-6. [DOI: 10.1097/cji.0000000000000254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
136 Asmar R, Yang J, Carvajal RD. Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag 2016;12:313-25. [PMID: 27013881 DOI: 10.2147/TCRM.S78039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
137 Sabanathan D, Lund ME, Campbell DH, Walsh BJ, Gurney H. Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target. Ther Adv Med Oncol 2021;13:17588359211022918. [PMID: 34646364 DOI: 10.1177/17588359211022918] [Reference Citation Analysis]
138 Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol 2017;35:39.e1-7. [PMID: 28341495 DOI: 10.1016/j.urolonc.2016.09.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
139 Sonpavde G, Pond GR, Bellmunt J. Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma. Eur Urol 2016;69:644-5. [PMID: 26415779 DOI: 10.1016/j.eururo.2015.09.015] [Reference Citation Analysis]
140 Li Y, Guo G, Song J, Cai Z, Yang J, Chen Z, Wang Y, Huang Y, Gao Q. B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway. J Cancer 2017;8:816-24. [PMID: 28382144 DOI: 10.7150/jca.17759] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
141 Miao L, Li J, Liu Q, Feng R, Das M, Lin CM, Goodwin TJ, Dorosheva O, Liu R, Huang L. Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. ACS Nano 2017;11:8690-706. [PMID: 28809532 DOI: 10.1021/acsnano.7b01786] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 14.8] [Reference Citation Analysis]
142 Liu J, Pan W, Yang D. The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection-A Mini Comment on the 2018 Medicine Nobel Prize. Virol Sin 2018;33:467-71. [PMID: 30570713 DOI: 10.1007/s12250-018-0077-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
143 Zajac M, Scott M, Ratcliffe M, Scorer P, Barker C, Al-Masri H, Rebelatto MC, Walker J. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. Diagn Pathol 2019;14:99. [PMID: 31477145 DOI: 10.1186/s13000-019-0873-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
144 Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for Immunotherapy: Current Developments and Challenges. Am Soc Clin Oncol Educ Book 2016;35:e493-503. [PMID: 27249758 DOI: 10.1200/EDBK_160766] [Cited by in Crossref: 21] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
145 Naidoo J, Li BT, Schindler K, Page DB. What does the future hold for immunotherapy in cancer? Ann Transl Med 2016;4:177. [PMID: 27275490 DOI: 10.21037/atm.2016.04.05] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
146 Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28:1036-41. [PMID: 28453692 DOI: 10.1093/annonc/mdx029] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 29.0] [Reference Citation Analysis]
147 Zeidan AM, Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion on Emerging Drugs 2016;21:283-300. [DOI: 10.1080/14728214.2016.1220534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
148 Yılmaz A, Mirili C, Bilici M, Tekin SB. Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia. J Oncol Pharm Pract 2020;26:1791-4. [PMID: 32237958 DOI: 10.1177/1078155220913081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
149 Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213:2835-2840. [PMID: 27903604 DOI: 10.1084/jem.20161462] [Cited by in Crossref: 150] [Cited by in F6Publishing: 148] [Article Influence: 25.0] [Reference Citation Analysis]
150 Chiang AC, Sequist LVD, Gilbert J, Conkling P, Thompson D, Marcoux JP, Gettinger S, Kowanetz M, Molinero L, O’hear C, Fassò M, Lam S, Gordon MS. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clinical Lung Cancer 2020;21:455-463.e4. [DOI: 10.1016/j.cllc.2020.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
151 Pietrobon V, Marincola FM. Hypoxia and the phenomenon of immune exclusion. J Transl Med 2021;19:9. [PMID: 33407613 DOI: 10.1186/s12967-020-02667-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
152 Diesendruck Y, Benhar I. Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges. Drug Resistance Updates 2017;30:39-47. [DOI: 10.1016/j.drup.2017.02.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
153 Brancato SJ, Lewi K, Agarwal PK. Evolving immunotherapy strategies in urothelial cancer. Am Soc Clin Oncol Educ Book 2015;:e284-90. [PMID: 25993187 DOI: 10.14694/EdBook_AM.2015.35.e284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
154 Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15:45-56. [PMID: 25534622 DOI: 10.1038/nri3790] [Cited by in Crossref: 339] [Cited by in F6Publishing: 320] [Article Influence: 48.4] [Reference Citation Analysis]
155 Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology. 2017;153:812-826. [PMID: 28624577 DOI: 10.1053/j.gastro.2017.06.007] [Cited by in Crossref: 265] [Cited by in F6Publishing: 272] [Article Influence: 53.0] [Reference Citation Analysis]
156 Bordon Y. Tumour immunology: Checkpoint parley. Nat Rev Immunol 2015;15:5. [PMID: 25475446 DOI: 10.1038/nri3792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
157 Jiang W, Li T, Guo J, Wang J, Jia L, Shi X, Yang T, Jiao R, Wei X, Feng Z, Tang Q, Ji G. Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Front Oncol 2021;11:546586. [PMID: 33777728 DOI: 10.3389/fonc.2021.546586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Leibowitz-amit R, Israel A, Gal M, Atenafu E, Symon Z, Portnoy O, Laufer M, Dotan Z, Ramon J, Avni D, Fridman E, Berger R. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer. Clinical Oncology 2016;28:790-6. [DOI: 10.1016/j.clon.2016.07.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
159 Sun X, Yan X, Zhuo W, Gu J, Zuo K, Liu W, Liang L, Gan Y, He G, Wan H, Gou X, Shi H, Hu J. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. Int J Mol Sci 2018;19:E1984. [PMID: 29986511 DOI: 10.3390/ijms19071984] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
160 Murakami Y, Matsumoto K, Shimizu Y, Ikeda M, Amano N, Shimura S, Ishii D, Sato Y, Iwamura M. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. Urol Oncol 2021;39:195.e15-23. [PMID: 33071109 DOI: 10.1016/j.urolonc.2020.09.034] [Reference Citation Analysis]
161 Chin YT, Wei PL, Ho Y, Nana AW, Changou CA, Chen YR, Yang YS, Hsieh MT, Hercbergs A, Davis PJ, Shih YJ, Lin HY. Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells. Endocr Relat Cancer 2018;25:533-45. [PMID: 29555649 DOI: 10.1530/ERC-17-0376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
162 Lian S, Xie R, Ye Y, Lu Y, Cheng Y, Xie X, Li S, Jia L. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. Sci Rep 2019;9:4532. [PMID: 30872703 DOI: 10.1038/s41598-019-40241-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
163 Chen M, Li J, Zhuang C, Cai Z. Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer. Oncotarget 2017;8:28176-86. [PMID: 28157695 DOI: 10.18632/oncotarget.14945] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
164 Martinez VG, Munera-Maravilla E, Bernardini A, Rubio C, Suarez-Cabrera C, Segovia C, Lodewijk I, Dueñas M, Martínez-Fernández M, Paramio JM. Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. Front Genet 2019;10:1125. [PMID: 31850055 DOI: 10.3389/fgene.2019.01125] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
165 Kottschade L, Brys A, Peikert T, Ryder M, Raffals L, Brewer J, Mosca P, Markovic S; Midwest Melanoma Partnership. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res 2016;26:469-80. [PMID: 27306502 DOI: 10.1097/CMR.0000000000000273] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
166 Mizugaki H, Yamamoto N, Murakami H, Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T, Takahashi T. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drugs 2016;34:596-603. [PMID: 27363843 DOI: 10.1007/s10637-016-0371-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
167 Marabelle A, Gray J. Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy: Tumor- and Immune-Targeted Monoclonal Antibodies. Pediatr Blood Cancer 2015;62:1317-25. [DOI: 10.1002/pbc.25508] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
168 Li QX, Feuer G, Ouyang X, An X. Experimental animal modeling for immuno-oncology. Pharmacol Ther 2017;173:34-46. [PMID: 28167217 DOI: 10.1016/j.pharmthera.2017.02.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
169 Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF. Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunol Res 2016;4:669-78. [PMID: 27312342 DOI: 10.1158/2326-6066.CIR-15-0215] [Cited by in Crossref: 74] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
170 Sundahl N, Rottey S, De Maeseneer D, Ost P. Pembrolizumab for the treatment of bladder cancer. Expert Rev Anticancer Ther 2018;18:107-14. [PMID: 29284318 DOI: 10.1080/14737140.2018.1421461] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
171 He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol 2017;12:814-23. [PMID: 28132868 DOI: 10.1016/j.jtho.2017.01.019] [Cited by in Crossref: 74] [Cited by in F6Publishing: 87] [Article Influence: 14.8] [Reference Citation Analysis]
172 Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC; German Dermatooncology Group (DeCOG). Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017;75:24-32. [PMID: 28214654 DOI: 10.1016/j.ejca.2016.12.038] [Cited by in Crossref: 108] [Cited by in F6Publishing: 92] [Article Influence: 21.6] [Reference Citation Analysis]
173 Zhou YW, Zhu YJ, Wang MN, Xie Y, Chen CY, Zhang T, Xia F, Ding ZY, Liu JY. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. Front Pharmacol 2019;10:1350. [PMID: 31849640 DOI: 10.3389/fphar.2019.01350] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
174 Ciccarese C, Iacovelli R, Bria E, Mosillo C, Bimbatti D, Fantinel E, Bisogno I, Brunelli M, Tortora G. Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. Semin Oncol 2019;46:65-72. [PMID: 30665685 DOI: 10.1053/j.seminoncol.2019.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
175 Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L, Cai H, Wang Y, Zeng N, Xu T, Zhou A, Zheng Y. Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget 2017;8:90215-24. [PMID: 29163822 DOI: 10.18632/oncotarget.21652] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
176 Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M, Barni S. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. European Journal of Cancer 2018;103:7-16. [DOI: 10.1016/j.ejca.2018.07.129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
177 Eich ML, Dyrskjøt L, Netto GJ. Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Arch 2017;471:271-80. [PMID: 28429075 DOI: 10.1007/s00428-017-2119-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
178 . Cancer Immunotherapy Scores Again. Cell 2015;160:7-9. [DOI: 10.1016/j.cell.2014.12.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
179 Hellmann MD, Friedman CF, Wolchok JD. Combinatorial Cancer Immunotherapies. Adv Immunol 2016;130:251-77. [PMID: 26923003 DOI: 10.1016/bs.ai.2015.12.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
180 Li F, Wang Y, Xie K, Fang Y, Du Y, Hou L, Tan W. The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials. Aging (Albany NY) 2021;13:20468-80. [PMID: 34424218 DOI: 10.18632/aging.203429] [Reference Citation Analysis]
181 Zhang F, Zheng Z, Barman AK, Wang Z, Wang L, Zeng W, Wang L, Qin Y, Pandey A, Zhang C, Liang W. Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity. Commun Biol 2021;4:78. [PMID: 33469123 DOI: 10.1038/s42003-020-01598-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
182 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 34.6] [Reference Citation Analysis]
183 Hacking S, Vitkovski T, Jain S, Jin C, Chavarria H, Wu D, Nasim M. Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma. Appl Immunohistochem Mol Morphol 2021;29:201-8. [PMID: 32842025 DOI: 10.1097/PAI.0000000000000868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Abe T, Matsumoto R, Shinohara N. Role of surgical consolidation in metastatic urothelial carcinoma. Curr Opin Urol 2016;26:573-80. [PMID: 27471992 DOI: 10.1097/MOU.0000000000000329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
185 Masson-lecomte A, Maillé P, Pineda S, Soyeux P, Sagrera A, Rava M, Lopez de Maturana E, Márquez M, Tardón A, Carrato A, Kogevinas M, de la Taille A, Hartmann A, Malats N, Real P, Allory Y. CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis. BLC 2019;5:159-69. [DOI: 10.3233/blc-180206] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
186 Emens LA. It's TIME for a biomarker-driven approach to cancer immunotherapy. J Immunother Cancer 2016;4:43. [PMID: 27532018 DOI: 10.1186/s40425-016-0147-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
187 Woldu SL, Şanli Ö, Lotan Y. Tackling non-muscle invasive bladder cancer in the clinic. Expert Rev Anticancer Ther 2017;17:467-80. [PMID: 28359179 DOI: 10.1080/14737140.2017.1313119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
188 Chen Z, Liu G, Hossain A, Danilova IG, Bolkov MA, Liu G, Tuzankina IA, Tan W. A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival. Hereditas 2019;156:24. [PMID: 31333338 DOI: 10.1186/s41065-019-0100-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
189 Song Y, Li Z, Xue W, Zhang M. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy 2019;11:515-29. [DOI: 10.2217/imt-2018-0173] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
190 Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15-25. [PMID: 27725639 DOI: 10.1038/nrurol.2016.175] [Cited by in Crossref: 121] [Cited by in F6Publishing: 124] [Article Influence: 20.2] [Reference Citation Analysis]
191 Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res 2015;3:1148-57. [PMID: 26014098 DOI: 10.1158/2326-6066.CIR-15-0059] [Cited by in Crossref: 249] [Cited by in F6Publishing: 151] [Article Influence: 35.6] [Reference Citation Analysis]
192 Rolvering C, Zimmer AD, Ginolhac A, Margue C, Kirchmeyer M, Servais F, Hermanns HM, Hergovits S, Nazarov PV, Nicot N, Kreis S, Haan S, Behrmann I, Haan C. The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by α-PD-L1 or α-IL6 antibodies. J Leukoc Biol 2018;104:969-85. [PMID: 30040142 DOI: 10.1002/JLB.MA1217-495R] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
193 Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018;31:214-34. [PMID: 29192647 DOI: 10.1038/modpathol.2017.156] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 27.2] [Reference Citation Analysis]
194 Dong B, Liang J, Li D, Song W, Zhao S, Ma Y, Song J, Zhu M, Yang T. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer. Front Genet 2021;12:696912. [PMID: 34512722 DOI: 10.3389/fgene.2021.696912] [Reference Citation Analysis]
195 Giraldo NA, Peske JD, Sautès-fridman C, Fridman WH. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Arch 2019;474:463-74. [DOI: 10.1007/s00428-018-02517-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
196 Sumimoto H, Takano A, Teramoto K, Daigo Y. Detection of neoantigen-reactive T cell clones based on the clonal expansion using next-generation sequencing of T cell receptor β complementarity-determining region 3. J Immunol Methods 2020;476:112679. [PMID: 31655052 DOI: 10.1016/j.jim.2019.112679] [Reference Citation Analysis]
197 Deng H, Tan S, Gao X, Zou C, Xu C, Tu K, Song Q, Fan F, Huang W, Zhang Z. Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. Acta Pharm Sin B 2020;10:358-73. [PMID: 32082979 DOI: 10.1016/j.apsb.2019.07.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
198 Kurtoglu M, Davarpanah NN, Qin R, Powles T, Rosenberg JE, Apolo AB. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clin Genitourin Cancer 2015;13:410-20. [PMID: 25862322 DOI: 10.1016/j.clgc.2015.02.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
199 Lin SY, Hang JF, Lin YY, Lai CR, Ho HL, Chou TY. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression. Int J Gynecol Pathol 2021;40:148-55. [PMID: 32897958 DOI: 10.1097/PGP.0000000000000682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Lopez-Beltran A, López-Rios F, Montironi R, Wildsmith S, Eckstein M. Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. Cancers (Basel) 2021;13:1424. [PMID: 33804698 DOI: 10.3390/cancers13061424] [Reference Citation Analysis]
201 Petrylak DP. Immunotherapy: The Wave of the Future in Bladder Cancer? Clinical Genitourinary Cancer 2017;15:S3-S17. [DOI: 10.1016/j.clgc.2017.05.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
202 Aversa I, Malanga D, Fiume G, Palmieri C. Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy. Int J Mol Sci 2020;21:E2378. [PMID: 32235561 DOI: 10.3390/ijms21072378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
203 Wu J, Abraham SN. The Roles of T cells in Bladder Pathologies. Trends Immunol 2021;42:248-60. [PMID: 33536141 DOI: 10.1016/j.it.2021.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
204 Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, Jöhrer K. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol 2016;9:116. [PMID: 27809856 DOI: 10.1186/s13045-016-0345-3] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 16.7] [Reference Citation Analysis]
205 Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M. Evolving adoptive cellular therapies in urological malignancies. Lancet Oncol 2017;18:e341-53. [PMID: 28593860 DOI: 10.1016/S1470-2045(17)30327-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
206 Fang D, Kitamura H. Cancer stem cells and epithelial-mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches. Int J Urol. 2018;25:7-17. [PMID: 28697535 DOI: 10.1111/iju.13404] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
207 Pan Z, Di S, Shi B, Jiang H, Shi Z, Liu Y, Wang Y, Luo H, Yu M, Wu X, Li Z. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein. Cancer Immunol Immunother. 2018;67:1621-1634. [PMID: 30078052 DOI: 10.1007/s00262-018-2221-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
208 Ebert PJR, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, Gould SE, Maecker H, Irving BA, Kim JM, Belvin M, Mellman I. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity. 2016;44:609-621. [PMID: 26944201 DOI: 10.1016/j.immuni.2016.01.024] [Cited by in Crossref: 357] [Cited by in F6Publishing: 322] [Article Influence: 59.5] [Reference Citation Analysis]
209 Seetharamu N, Preeshagul IR, Sullivan KM. New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. Lung Cancer (Auckl) 2017;8:67-78. [PMID: 28761384 DOI: 10.2147/LCTT.S113177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
210 Zhang G, Shi W, Jia E, Zhang L, Han Y, Rodriguez R, Ma T. FOXO3A Expression in Upper Tract Urothelial Carcinoma. Front Oncol 2021;11:603681. [PMID: 33959492 DOI: 10.3389/fonc.2021.603681] [Reference Citation Analysis]
211 Houédé N, Locker G, Lucas C, Parra HS, Basso U, Spaeth D, Tambaro R, Basterretxea L, Morelli F, Theodore C, Lusuardi L, Lainez N, Guillot A, Tonini G, Bielle J, Del Muro XG. Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. BMC Cancer 2016;16:752. [PMID: 27664126 DOI: 10.1186/s12885-016-2782-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
212 Herrera-martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocrine-Related Cancer 2019;26:R157-79. [DOI: 10.1530/erc-18-0354] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
213 Zhong JH, Luo CP, Zhang CY, Li LQ. Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients. J Hepatocell Carcinoma 2017;4:11-3. [PMID: 28116284 DOI: 10.2147/JHC.S122807] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
214 McNiel EA, Tsichlis PN. Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. Signal Transduct Target Ther 2017;2:16045. [PMID: 28515962 DOI: 10.1038/sigtrans.2016.45] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
215 Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, Oh YL, Chung JH. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 2017;24:97-106. [PMID: 28093480 DOI: 10.1530/ERC-16-0421] [Cited by in Crossref: 61] [Cited by in F6Publishing: 37] [Article Influence: 15.3] [Reference Citation Analysis]
216 Leblond MM, Zdimerova H, Desponds E, Verdeil G. Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. Cancers (Basel) 2021;13:4712. [PMID: 34572939 DOI: 10.3390/cancers13184712] [Reference Citation Analysis]
217 Zheng B, Wang J, Cai W, Lao I, Shi Y, Luo X, Yan W. Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas. Ann Transl Med 2019;7:387. [PMID: 31555701 DOI: 10.21037/atm.2019.07.43] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
218 Tully KH, Jütte H, Wirtz RM, Jarczyk J, Santiago-Walker A, Zengerling F, Breyer J, Sikic D, Kriegmair MC, von Hardenberg J, Wullich B, Taubert H, Weyerer V, Stoehr R, Bolenz C, Burger M, Porubsky S, Hartmann A, Roghmann F, Erben P, Eckstein M. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. Urology 2021:S0090-4295(21)00485-4. [PMID: 34153367 DOI: 10.1016/j.urology.2021.05.055] [Reference Citation Analysis]
219 Shao Z, Wang AZ, George DJ, Zhang T. Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian J Urol 2016;3:268-77. [PMID: 29264195 DOI: 10.1016/j.ajur.2016.08.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
220 Feng C, Cao LJ, Song HF, Xu P, Chen H, Xu JC, Zhu XY, Zhang XG, Wang XF. Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters. Viral Immunol 2015;28:418-24. [PMID: 26266813 DOI: 10.1089/vim.2015.0062] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
221 Na L, Bai Y, Sun Y, Wang Z, Wang W, Yuan L, Zhao C. Identification of 9-Core Immune-Related Genes in Bladder Urothelial Carcinoma Prognosis. Front Oncol 2020;10:1142. [PMID: 32733809 DOI: 10.3389/fonc.2020.01142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
222 Powles T, Nickles D, Van Allen E, Chappey C, Zou W, Kowanetz M, Kadel E, Denker M, Boyd Z, Vogelzang N, Kim J, Bellmunt J, Loriot Y, Drake CG, O'hear C, Fasso M, Hegde P, Mariathasan S. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). j immunotherapy cancer 2015;3. [DOI: 10.1186/2051-1426-3-s2-p83] [Cited by in Crossref: 11] [Article Influence: 1.6] [Reference Citation Analysis]
223 Ahmed M, Barakat K. The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study. Biochemistry 2017;56:5428-39. [PMID: 28898057 DOI: 10.1021/acs.biochem.7b00655] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
224 Bertolini G, Bergamaschi L, Ferrari A, Renne SL, Collini P, Gardelli C, Barisella M, Centonze G, Chiaravalli S, Paolino C, Milione M, Massimino M, Casanova M, Gasparini P. PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. BMC Cancer 2018;18:652. [PMID: 29898687 DOI: 10.1186/s12885-018-4554-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
225 Shen H, Sun T, Hoang HH, Burchfield JS, Hamilton GF, Mittendorf EA, Ferrari M. Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol 2017;34:114-22. [PMID: 28947107 DOI: 10.1016/j.smim.2017.09.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
226 Pennock GK, Chow LQ. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist. 2015;20:812-822. [PMID: 26069281 DOI: 10.1634/theoncologist.2014-0422] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 15.4] [Reference Citation Analysis]
227 Pignot G, Houede N. [Immunotherapy in urology: Concept and results]. Prog Urol 2019;29:922-8. [PMID: 31477432 DOI: 10.1016/j.purol.2019.08.267] [Reference Citation Analysis]
228 Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273-290. [PMID: 26977780 DOI: 10.1038/nrclinonc.2016.25] [Cited by in Crossref: 544] [Cited by in F6Publishing: 503] [Article Influence: 90.7] [Reference Citation Analysis]
229 Lv H, Zhang J, Sun K, Nie C, Chen B, Wang J, Xu W, Wang S, Liu Y, Chen X. Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. Front Oncol 2020;10:580045. [PMID: 33598422 DOI: 10.3389/fonc.2020.580045] [Reference Citation Analysis]
230 Verschueren E, Husain B, Yuen K, Sun Y, Paduchuri S, Senbabaoglu Y, Lehoux I, Arena TA, Wilson B, Lianoglou S, Bakalarski C, Franke Y, Chan P, Wong AW, Gonzalez LC, Mariathasan S, Turley SJ, Lill JR, Martinez-Martin N. The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Clinical Outcome. Cell 2020;182:329-344.e19. [PMID: 32589946 DOI: 10.1016/j.cell.2020.06.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
231 Fulkerson CM, Dhawan D, Ratliff TL, Hahn NM, Knapp DW. Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs. Int J Genomics 2017;2017:6589529. [PMID: 28487862 DOI: 10.1155/2017/6589529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
232 Ghatalia P, Morgan CJ, Sonpavde G. Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. Crit Rev Oncol Hematol. 2016;98:122-136. [PMID: 26597016 DOI: 10.1016/j.critrevonc.2015.10.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
233 Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, Fassò M, Osborne S, Molinero L, O’hear C, Grossman W, Baehring J. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol 2018;140:317-28. [DOI: 10.1007/s11060-018-2955-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
234 Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis 2017;56:221-8. [PMID: 28163164 DOI: 10.1016/j.ijid.2017.01.028] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 14.0] [Reference Citation Analysis]
235 Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Front Immunol 2019;10:1337. [PMID: 31258527 DOI: 10.3389/fimmu.2019.01337] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 16.7] [Reference Citation Analysis]
236 El Jabbour T, Ross JS, Sheehan CE, Affolter KE, Geiersbach KB, Boguniewicz A, Ainechi S, Bronner MP, Jones DM, Lee H. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. J Clin Pathol 2018;71:46-51. [PMID: 28667193 DOI: 10.1136/jclinpath-2017-204525] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
237 Aine M, Eriksson P, Liedberg F, Höglund M, Sjödahl G. On Molecular Classification of Bladder Cancer: Out of One, Many. Eur Urol 2015;68:921-3. [PMID: 26215606 DOI: 10.1016/j.eururo.2015.07.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
238 Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016;22:26-36. [PMID: 26735408 DOI: 10.1038/nm.4015] [Cited by in Crossref: 216] [Cited by in F6Publishing: 206] [Article Influence: 36.0] [Reference Citation Analysis]
239 Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine DA, Zamarin D. Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. J Natl Cancer Inst 2018;110:787-90. [PMID: 29365144 DOI: 10.1093/jnci/djx277] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 22.7] [Reference Citation Analysis]
240 Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 2016;41:23-31. [PMID: 27240055 DOI: 10.1016/j.coi.2016.05.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 11.2] [Reference Citation Analysis]
241 Furuse M, Nonoguchi N, Omura N, Shirahata M, Iwasaki K, Inui T, Kuroiwa T, Kuwabara H, Miyatake SI. Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report. Neurol Med Chir (Tokyo) 2017;57:191-7. [PMID: 28331101 DOI: 10.2176/nmc.cr.2016-0330] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
242 Tu MM, Ng TL, De Jong FC, Zuiverloon TCM, Fazzari FGT, Theodorescu D. Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. Bladder Cancer 2019;5:131-45. [PMID: 33365377 DOI: 10.3233/BLC-190218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
243 Levingston CA, Young MR. Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies. Int J Cancer 2017;140:1609-19. [PMID: 27914100 DOI: 10.1002/ijc.30543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
244 Mainwaring A, Bullock N, Ellul T, Hughes O, Featherstone J. The top 100 most cited manuscripts in bladder cancer: A bibliometric analysis (review article). International Journal of Surgery 2020;75:130-8. [DOI: 10.1016/j.ijsu.2020.01.128] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
245 Watanabe M, Kuwata T, Setsuda A, Tokunaga M, Kaito A, Sugita S, Tonouchi A, Kinoshita T, Nagino M. Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry. Sci Rep 2021;11:4165. [PMID: 33603111 DOI: 10.1038/s41598-021-83711-1] [Reference Citation Analysis]
246 Du Y, Liang X, Li Y, Sun T, Xue H, Jin Z, Tian J. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments. Cancer Letters 2018;414:230-8. [DOI: 10.1016/j.canlet.2017.11.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
247 Post CCB, Westermann AM, Bosse T, Creutzberg CL, Kroep JR. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol Hematol 2020;152:102973. [PMID: 32497971 DOI: 10.1016/j.critrevonc.2020.102973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
248 Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JI, Culp WTN, Sparger EE, Rebhun RB, Monjazeb AM, Murphy WJ, Canter RJ. Canine cancer immunotherapy studies: linking mouse and human. J Immunother Cancer 2016;4:97. [PMID: 28031824 DOI: 10.1186/s40425-016-0200-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
249 Green MA, Waddell JA, Solimando DA Jr. Drug Monographs: Atezolizumab and Everolimus. Hosp Pharm 2016;51:810-4. [PMID: 27928185 DOI: 10.1310/hpj5110-810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
250 Ali HR, Dariush A, Provenzano E, Bardwell H, Abraham JE, Iddawela M, Vallier AL, Hiller L, Dunn JA, Bowden SJ, Hickish T, McAdam K, Houston S, Irwin MJ, Pharoah PD, Brenton JD, Walton NA, Earl HM, Caldas C. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res 2016;18:21. [PMID: 26882907 DOI: 10.1186/s13058-016-0682-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
251 Acharya AP, Sinha M, Ratay ML, Ding X, Balmert SC, Workman CJ, Wang Y, Vignali DAA, Little SR. Localized Multi-Component Delivery Platform Generates Local and Systemic Anti-Tumor Immunity. Adv Funct Mater 2017;27:1604366. [DOI: 10.1002/adfm.201604366] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
252 Awad MM, Hammerman PS. Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers. J Clin Oncol 2015;33:1993-4. [PMID: 25918290 DOI: 10.1200/JCO.2015.61.4172] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
253 Hurwitz ME, Sokhn J, Petrylak DP. Cancer immunotherapy: new applications in urologic oncology. Curr Opin Urol 2016;26:535-42. [PMID: 27584025 DOI: 10.1097/MOU.0000000000000345] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
254 Lopez J, Harris S, Roda D, Yap TA. Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Transl Oncogenomics 2015;7:1-11. [PMID: 26609214 DOI: 10.4137/TOG.S30533] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
255 Obara W, Kanehira M, Katagiri T, Kato R, Kato Y, Takata R. Present status and future perspective of peptide-based vaccine therapy for urological cancer. Cancer Sci 2018;109:550-9. [PMID: 29345737 DOI: 10.1111/cas.13506] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
256 Balar AV, Milowsky MI. Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development. Urol Clin North Am 2015;42:217-24, viii-ix. [PMID: 25882563 DOI: 10.1016/j.ucl.2015.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
257 Loriot Y, Sternberg CN, Castellano D, Oosting SF, Dumez H, Huddart R, Vianna K, Alonso Gordoa T, Skoneczna I, Fay AP, Nolè F, Massari F, Brasiuniene B, Maroto P, Fear S, Di Nucci F, de Ducla S, Choy E. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. Eur J Cancer 2020;138:202-11. [PMID: 32905959 DOI: 10.1016/j.ejca.2020.07.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
258 Albany C, Sonpavde G. Docetaxel for the treatment of bladder cancer. Expert Opin Investig Drugs 2015;24:1657-64. [PMID: 26535615 DOI: 10.1517/13543784.2015.1109626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
259 Janev A, Ramuta TŽ, Tratnjek L, Sardoč Ž, Obradović H, Mojsilović S, Taskovska M, Smrkolj T, Kreft ME. Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models. Front Bioeng Biotechnol 2021;9:690358. [PMID: 34249888 DOI: 10.3389/fbioe.2021.690358] [Reference Citation Analysis]
260 Hu Y, Chen W, Yan Z, Ma J, Zhu F, Huo J. Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2019;98:e14006. [PMID: 30653106 DOI: 10.1097/MD.0000000000014006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
261 Casadei C, Dizman N, Schepisi G, Cursano MC, Basso U, Santini D, Pal SK, De Giorgi U. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther Adv Med Oncol 2019;11:1758835919890285. [PMID: 31803255 DOI: 10.1177/1758835919890285] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
262 Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. J Natl Cancer Inst 2019;111:118-28. [PMID: 30561713 DOI: 10.1093/jnci/djy196] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
263 Li T, Pan S, Gao S, Xiang W, Sun C, Cao W, Xu H. Diselenide-Pemetrexed Assemblies for Combined Cancer Immuno-, Radio-, and Chemotherapies. Angew Chem Int Ed Engl 2020;59:2700-4. [PMID: 31805209 DOI: 10.1002/anie.201914453] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
264 Taki S, Matsuoka K, Nishinaga Y, Takahashi K, Yasui H, Koike C, Shimizu M, Sato M, Sato K. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity. J Immunother Cancer 2021;9:e003036. [PMID: 34725216 DOI: 10.1136/jitc-2021-003036] [Reference Citation Analysis]
265 Ozimski LL, Gremmelspacher D, Aceto N. A fatal affair: Circulating tumor cell relationships that shape metastasis. iScience 2021;24:103073. [PMID: 34568794 DOI: 10.1016/j.isci.2021.103073] [Reference Citation Analysis]
266 Lorenzo-Sanz L, Muñoz P. Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. Cancer Microenviron 2019;12:119-32. [PMID: 31583529 DOI: 10.1007/s12307-019-00232-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
267 Safi M, Ahmed H, Al-Azab M, Xia YL, Shan X, Al-Radhi M, Al-Danakh A, Shopit A, Liu J. PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. J Adv Res 2021;29:45-54. [PMID: 33842004 DOI: 10.1016/j.jare.2020.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Ochoa AE, Choi W, Su X, Siefker-Radtke A, Czerniak B, Dinney C, McConkey DJ. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget 2016;7:80164-74. [PMID: 27845906 DOI: 10.18632/oncotarget.13284] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
269 Arriola E, Ottensmeier C. TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy 2016;8:511-9. [PMID: 27140406 DOI: 10.2217/imt-2016-0015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
270 Schumacher TN, Kesmir C, van Buuren MM. Biomarkers in cancer immunotherapy. Cancer Cell 2015;27:12-4. [PMID: 25584891 DOI: 10.1016/j.ccell.2014.12.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 11.7] [Reference Citation Analysis]
271 Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M, Belani CP. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget 2016;7:56233-40. [PMID: 27191652 DOI: 10.18632/oncotarget.9316] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
272 Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß C, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European Journal of Cancer 2019;106:234-43. [DOI: 10.1016/j.ejca.2018.11.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 12.3] [Reference Citation Analysis]
273 Horn T, Laus J, Seitz AK, Maurer T, Schmid SC, Wolf P, Haller B, Winkler M, Retz M, Nawroth R, Gschwend JE, Kübler HR, Slotta-Huspenina J. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol 2016;34:181-7. [PMID: 26055646 DOI: 10.1007/s00345-015-1615-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
274 Wang YN, Lee HH, Hsu JL, Yu D, Hung MC. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci 2020;27:77. [PMID: 32620165 DOI: 10.1186/s12929-020-00670-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
275 Lee SS, Bindokas VP, Kron SJ. Multiplex three-dimensional optical mapping of tumor immune microenvironment. Sci Rep 2017;7:17031. [PMID: 29208908 DOI: 10.1038/s41598-017-16987-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
276 Qiu L, Tan H, Lin Q, Si Z, Mao W, Wang T, Fu Z, Cheng D, Shi H. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. Mol Imaging Biol 2020;22:842-53. [PMID: 31741201 DOI: 10.1007/s11307-019-01441-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
277 Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016;21:462-73. [DOI: 10.1007/s10147-016-0959-z] [Reference Citation Analysis]
278 Netto GJ, Tafe LJ. Emerging Bladder Cancer Biomarkers and Targets of Therapy. Urol Clin North Am 2016;43:63-76. [PMID: 26614029 DOI: 10.1016/j.ucl.2015.08.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
279 Cheng W, Fu D, Xu F, Zhang Z. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis 2018;7:2. [PMID: 29358573 DOI: 10.1038/s41389-017-0013-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
280 Campbell MT, Shah AY, Matin SF, Siefker-radtke AO. Optimizing management of upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 2017;35:492-8. [DOI: 10.1016/j.urolonc.2017.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
281 Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 2017;7:5532. [PMID: 28717238 DOI: 10.1038/s41598-017-06002-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 14.6] [Reference Citation Analysis]
282 Langhammer S, Scheerer J. Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget 2017;8:43555-70. [PMID: 28402937 DOI: 10.18632/oncotarget.16674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
283 Gaynor N, Crown J, Collins DM. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. Semin Cancer Biol 2020:S1044-579X(20)30152-8. [PMID: 32623044 DOI: 10.1016/j.semcancer.2020.06.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
284 Sui W, Lim EA, Joel Decastro G, McKiernan JM, Anderson CB. Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy. Bladder Cancer 2017;3:181-9. [PMID: 28824946 DOI: 10.3233/BLC-170107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
285 Nguyen A, Ramesh A, Kumar S, Nandi D, Brouillard A, Wells A, Pobezinsky L, Osborne B, Kulkarni AA. Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. Sci Adv 2020;6:eabc2777. [PMID: 33008894 DOI: 10.1126/sciadv.abc2777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
286 Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging 2017;44:2310-25. [PMID: 28815334 DOI: 10.1007/s00259-017-3802-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
287 Wang L, Yao R, Zhang L, Fan C, Ma L, Liu J. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. Int Immunopharmacol 2019;70:498-503. [PMID: 30875561 DOI: 10.1016/j.intimp.2019.01.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
288 Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, Davidson NE, Huang Y. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene 2019;38:390-405. [PMID: 30111819 DOI: 10.1038/s41388-018-0451-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
289 Xu G, Sun L, Li Y, Xie F, Zhou X, Yang H, Du S, Xu H, Mao Y. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Front Oncol 2019;9:897. [PMID: 31620360 DOI: 10.3389/fonc.2019.00897] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
290 Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat Rev 2017;54:58-67. [PMID: 28214651 DOI: 10.1016/j.ctrv.2017.01.007] [Cited by in Crossref: 198] [Cited by in F6Publishing: 187] [Article Influence: 39.6] [Reference Citation Analysis]
291 Xu Y, Fu Y, Zhu B, Wang J, Zhang B. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Front Immunol 2020;11:2023. [PMID: 33123120 DOI: 10.3389/fimmu.2020.02023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
292 Fizazi K. Biennial report on genitourinary cancers. Eur J Cancer 2016;66:125-30. [PMID: 27569040 DOI: 10.1016/j.ejca.2016.06.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
293 You W, Liu M, Miao JD, Liao YQ, Song YB, Cai DK, Gao Y, Peng H. A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. J Cancer 2018;9:1200-6. [PMID: 29675101 DOI: 10.7150/jca.22361] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
294 Goldstein DA, Ratain MJ. Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Cancer Chemother Pharmacol 2019;84:1153-5. [DOI: 10.1007/s00280-019-03971-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
295 Bassani-sternberg M. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens. In: Schrader M, Fricker L, editors. Peptidomics. New York: Springer; 2018. pp. 209-21. [DOI: 10.1007/978-1-4939-7537-2_14] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
296 Bernard-Tessier A, Baldini C, Castanon E, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C, Ammari S. Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunol Immunother 2021;70:221-32. [PMID: 32700090 DOI: 10.1007/s00262-020-02647-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
297 Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 2019;25:141-51. [PMID: 30420753 DOI: 10.1038/s41591-018-0221-5] [Cited by in Crossref: 207] [Cited by in F6Publishing: 216] [Article Influence: 51.8] [Reference Citation Analysis]
298 Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell 2016;167:1540-1554.e12. [PMID: 27912061 DOI: 10.1016/j.cell.2016.11.022] [Cited by in Crossref: 441] [Cited by in F6Publishing: 418] [Article Influence: 88.2] [Reference Citation Analysis]
299 Mony JT, Zhang L, Ma T, Grabosch S, Tirodkar TS, Brozick J, Tseng G, Elishaev E, Edwards RP, Huang X, Vlad AM. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunol Immunother 2015;64:1095-108. [PMID: 25998800 DOI: 10.1007/s00262-015-1712-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
300 Hussain SA, Birtle A, Crabb S, Huddart R, Small D, Summerhayes M, Jones R, Protheroe A. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. Eur Urol Oncol 2018;1:486-500. [PMID: 31158093 DOI: 10.1016/j.euo.2018.05.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
301 Yu JW, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S, Katlinskaya Y, Kaczynski H, Conner M, Benson W, Hahn A, Seestaller-Wehr L, Bi M, Vitali NJ, Tsvetkov L, Halsey W, Hughes A, Traini C, Zhou H, Jing J, Lee T, Figueroa DJ, Brett S, Hopson CB, Smothers JF, Hoos A, Srinivasan R. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS One 2018;13:e0206223. [PMID: 30388137 DOI: 10.1371/journal.pone.0206223] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 13.8] [Reference Citation Analysis]
302 Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 2021;18:345-62. [PMID: 33580222 DOI: 10.1038/s41571-021-00473-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
303 Linder S, van der Poel HG, Bergman AM, Zwart W, Prekovic S. Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocr Relat Cancer 2018;26:R31-52. [PMID: 30382692 DOI: 10.1530/ERC-18-0289] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
304 Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol 2017;71:237-46. [PMID: 27567210 DOI: 10.1016/j.eururo.2016.08.024] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
305 Deng H, Zhang Z. The application of nanotechnology in immune checkpoint blockade for cancer treatment. J Control Release 2018;290:28-45. [PMID: 30287266 DOI: 10.1016/j.jconrel.2018.09.026] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
306 Resch I, Shariat SF, Gust KM. PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. Memo 2018;11:43-6. [PMID: 29606979 DOI: 10.1007/s12254-018-0396-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
307 Packiam VT, Johnson SC, Steinberg GD. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin. Cancer 2017;123:390-400. [PMID: 28112819 DOI: 10.1002/cncr.30392] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
308 Zhang J, Quadri S, Wolfgang CL, Zheng L. New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 2018;6:E87. [PMID: 30104497 DOI: 10.3390/biomedicines6030087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
309 Mehta A, Oklu R, Sheth RA. Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? Gastroenterol Res Pract. 2016;2016:9251375. [PMID: 27051417 DOI: 10.1155/2016/9251375] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
310 Chen T, Xu XY, Zhou PH. Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer. 2016;35:49. [PMID: 27233623 DOI: 10.1186/s40880-016-0111-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
311 Errico A. Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nat Rev Clin Oncol 2015;12:63. [PMID: 25533942 DOI: 10.1038/nrclinonc.2014.221] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
312 Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H; Japan Urological Oncology Group. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 2021;112:760-73. [PMID: 33283385 DOI: 10.1111/cas.14762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
313 Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, Buonaguro L, Ciliberto G, Brauchli P, Pignata S. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy? Cancer Treat Rev. 2016;48:61-68. [PMID: 27362548 DOI: 10.1016/j.ctrv.2016.06.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 11.8] [Reference Citation Analysis]
314 Bagaria SP, Gatalica Z, Maney T, Serie D, Parasramka M, Attia S, Krishna M, Joseph RW. Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. Front Oncol. 2018;8:71. [PMID: 29623256 DOI: 10.3389/fonc.2018.00071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
315 Li Z, Li B, Li L, Wang G, Li Y, Fu R, Ming Y, Ni R, Wang J, Ye G, Chen J. The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells. Onco Targets Ther 2020;13:12225-41. [PMID: 33273828 DOI: 10.2147/OTT.S281397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
316 Marcq G, Souhami L, Cury FL, Salimi A, Aprikian A, Tanguay S, Vanhuyse M, Rajan R, Brimo F, Mansure JJ, Kassouf W. Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys 2021;110:738-41. [PMID: 33421558 DOI: 10.1016/j.ijrobp.2020.12.033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
317 Accogli T, Bruchard M, Végran F. Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers (Basel) 2021;13:373. [PMID: 33498483 DOI: 10.3390/cancers13030373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
318 Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. [PMID: 28018338 DOI: 10.3389/fimmu.2016.00550] [Cited by in Crossref: 219] [Cited by in F6Publishing: 226] [Article Influence: 36.5] [Reference Citation Analysis]
319 Braun DA, Wu CJ. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer J 2017;23:115-24. [PMID: 28410299 DOI: 10.1097/PPO.0000000000000257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
320 Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015;10:e0130142. [PMID: 26086854 DOI: 10.1371/journal.pone.0130142] [Cited by in Crossref: 294] [Cited by in F6Publishing: 283] [Article Influence: 42.0] [Reference Citation Analysis]
321 Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, Doeberitz MVK, Jäger D, Springfeld C. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Cold Spring Harb Mol Case Stud 2017;3:a001974. [PMID: 28619747 DOI: 10.1101/mcs.a001974] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
322 Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology directed therapy for advanced bladder cancer. Nat Rev Urol 2019;16:465-83. [PMID: 31289379 DOI: 10.1038/s41585-019-0208-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
323 Schreiner J, Thommen DS, Herzig P, Bacac M, Klein C, Roller A, Belousov A, Levitsky V, Savic S, Moersig W, Uhlenbrock F, Heinzelmann-Schwarz VA, Umana P, Pisa P, von Bergwelt-Baildon M, Lardinois D, Müller P, Karanikas V, Zippelius A. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology 2016;5:e1062969. [PMID: 27057429 DOI: 10.1080/2162402X.2015.1062969] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
324 Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med 2019;7:690. [PMID: 31930091 DOI: 10.21037/atm.2019.10.24] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
325 Reichardt W, von Elverfeldt D. Preclinical Applications of Magnetic Resonance Imaging in Oncology. Recent Results Cancer Res 2020;216:405-37. [PMID: 32594394 DOI: 10.1007/978-3-030-42618-7_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 Grimm MO, Winkler Y, Fetter I, Oppel-Heuchel H. [Renaissance of immuno-oncology for urological tumors : Current status]. Urologe A 2016;55:621-6. [PMID: 27119960 DOI: 10.1007/s00120-016-0107-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
327 Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265-276. [PMID: 25797516 DOI: 10.1016/j.it.2015.02.008] [Cited by in Crossref: 517] [Cited by in F6Publishing: 493] [Article Influence: 73.9] [Reference Citation Analysis]
328 Kim HM, Lee J, Koo JS. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer 2017;17:690. [PMID: 29041905 DOI: 10.1186/s12885-017-3670-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
329 Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA. PD-L1 inhibitors in the pipeline: Promise and progress. Oncoimmunology 2017;7:e1365209. [PMID: 29296516 DOI: 10.1080/2162402X.2017.1365209] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
330 Persigehl T, Poeppel TD, Sedlaczek O. [Radiological response assessment of modern immunotherapy using iRECIST]. Radiologe 2017;57:826-33. [PMID: 28812098 DOI: 10.1007/s00117-017-0289-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
331 Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 2016;34:3733-9. [PMID: 27354476 DOI: 10.1200/JCO.2016.67.3467] [Cited by in Crossref: 415] [Cited by in F6Publishing: 227] [Article Influence: 83.0] [Reference Citation Analysis]
332 He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 2018;149:253-61. [PMID: 29425258 DOI: 10.1093/ajcp/aqx162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
333 Endris V, Buchhalter I, Allgäuer M, Rempel E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Penzel R, Weichert W, Glimm H, Fröhling S, Winter H, Herth F, Thomas M, Schirmacher P, Budczies J, Stenzinger A. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Int J Cancer 2019;144:2303-12. [PMID: 30446996 DOI: 10.1002/ijc.32002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
334 Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 2017;9:eaah3560. [PMID: 28251903 DOI: 10.1126/scitranslmed.aah3560] [Cited by in Crossref: 318] [Cited by in F6Publishing: 282] [Article Influence: 63.6] [Reference Citation Analysis]
335 Balar AV. Immune Checkpoint Blockade in Metastatic Urothelial Cancer. J Clin Oncol 2017;35:2109-12. [PMID: 28481707 DOI: 10.1200/JCO.2017.72.8444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
336 Apolo AB. PDL1: The Illusion of an Ideal Biomarker. Eur Urol Focus 2016;1:269-71. [PMID: 28723398 DOI: 10.1016/j.euf.2015.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
337 Hong Y, Feng Y, Sun H, Zhang B, Wu H, Zhu Q, Li Y, Zhang T, Zhang Y, Cui X, Li Z, Song X, Li K, Liu M, Liu Y. Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio 2021;11:782-92. [PMID: 33527708 DOI: 10.1002/2211-5463.13102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX. COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 2018;17:474-83. [PMID: 29284644 DOI: 10.1158/1535-7163.MCT-16-0818] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
339 Hue JJ, Bingmer K, Sugumar K, Markt SC, Rothermel LD, Hardacre JM, Ammori JB, Winter JM, Ocuin LM. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. J Pancreat Cancer 2021;7:31-8. [PMID: 33937617 DOI: 10.1089/pancan.2021.0003] [Reference Citation Analysis]
340 Aoun F, Rassy EE, Assi T, Albisinni S, Katan J. Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. Immunotherapy 2017;9:451-60. [PMID: 28357911 DOI: 10.2217/imt-2017-0007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
341 Goodspeed A, Jean A, Theodorescu D, Costello JC. A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition. Bladder Cancer 2018;4:269-82. [PMID: 30112438 DOI: 10.3233/BLC-170161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
342 Xipell M, Victoria I, Hoffmann V, Villarreal J, García-Herrera A, Reig O, Rodas L, Blasco M, Poch E, Mellado B, Quintana LF. Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. Oncoimmunology 2018;7:e1445952. [PMID: 29900063 DOI: 10.1080/2162402X.2018.1445952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
343 Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest 2019;129:616-30. [PMID: 30457978 DOI: 10.1172/JCI122216] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 12.7] [Reference Citation Analysis]
344 de Lorenzo F, Wait S, Karaca B, Britten CM, van den Bulcke M; European Expert Group on Immuno-Oncology. Greater patient access to immuno-oncology therapies-what can policymakers do? Ecancermedicalscience 2015;9:ed48. [PMID: 25729428 DOI: 10.3332/ecancer.2015.ed48] [Reference Citation Analysis]
345 Zou R, Wang Y, Ye F, Zhang X, Wang M, Cui S. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clin Transl Oncol 2021. [PMID: 34002348 DOI: 10.1007/s12094-021-02637-2] [Reference Citation Analysis]
346 Reguera-Nuñez E, Xu P, Chow A, Man S, Hilberg F, Kerbel RS. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. J Exp Clin Cancer Res 2019;38:16. [PMID: 30635009 DOI: 10.1186/s13046-018-0999-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
347 Nagano M, Saito K, Kozuka Y, Ichishi M, Yuasa H, Noro A, Imai N, Shibusawa M, Kimoto M, Ishitobi M, Tono Y, Oda H, Ishihara M, Mizuno T, Ogawa T, Katayama N. CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression. Oncol Lett 2021;21:36. [PMID: 33262828 DOI: 10.3892/ol.2020.12297] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
348 Kim J, Akbani R, Creighton CJ, Lerner SP, Weinstein JN, Getz G, Kwiatkowski DJ. Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res 2015;21:4514-24. [PMID: 26473186 DOI: 10.1158/1078-0432.CCR-14-1215] [Cited by in Crossref: 75] [Cited by in F6Publishing: 45] [Article Influence: 12.5] [Reference Citation Analysis]
349 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509-2520. [PMID: 26028255 DOI: 10.1056/nejmoa1500596] [Cited by in Crossref: 4650] [Cited by in F6Publishing: 2768] [Article Influence: 664.3] [Reference Citation Analysis]
350 Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, Jost C, Fransen MF, Buser RB, Kowanetz M, Rommel K, Matos I, Colombetti S, Belousov A, Karanikas V, Ossendorp F, Hegde PS, Chen DS, Umana P, Perro M, Klein C, Xu W. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med 2020;12:eaav7431. [PMID: 32161104 DOI: 10.1126/scitranslmed.aav7431] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 83.0] [Reference Citation Analysis]
351 Thibault C. Immunothérapie dans les carcinomes urothéliaux. Bull Cancer 2018;105 Suppl 1:S43-9. [PMID: 30595198 DOI: 10.1016/S0007-4551(18)30389-8] [Reference Citation Analysis]
352 Tsai TF, Lin JF, Lin YC, Chou KY, Chen HE, Ho CY, Chen PC, Hwang TI. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway. Biosci Rep 2019;39:BSR20190362. [PMID: 31341011 DOI: 10.1042/BSR20190362] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
353 Dave K, Ali A, Magalhaes M. Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Sci Rep 2020;10:9705. [PMID: 32546692 DOI: 10.1038/s41598-020-66257-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
354 Carvajal-hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. j immunotherapy cancer 2017;5. [DOI: 10.1186/s40425-017-0285-7] [Reference Citation Analysis]
355 Chang CY, Tai JA, Li S, Nishikawa T, Kaneda Y. Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity. Oncotarget 2016;7:42195-207. [PMID: 27259252 DOI: 10.18632/oncotarget.9743] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
356 Abe T, Ishizaki J, Kikuchi H, Minami K, Matsumoto R, Harabayashi T, Sazawa A, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Maruyama S, Murai S, Shinohara N. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan. Urol Oncol 2017;35:38.e1-8. [PMID: 27693091 DOI: 10.1016/j.urolonc.2016.08.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
357 Schneider AK, Chevalier MF, Derré L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol 2019;16:613-30. [PMID: 31501534 DOI: 10.1038/s41585-019-0226-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
358 Yu J, Mao W, Sun S, Hu Q, Wang C, Xu Z, Liu R, Chen S, Xu B, Chen M. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer. Cancer Manag Res 2022;14:67-88. [PMID: 35023971 DOI: 10.2147/CMAR.S346240] [Reference Citation Analysis]
359 de Ruiter JR, Wessels LFA, Jonkers J. Mouse models in the era of large human tumour sequencing studies. Open Biol 2018;8:180080. [PMID: 30111589 DOI: 10.1098/rsob.180080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
360 Ning YM, Suzman D, Maher VE, Zhang L, Tang S, Ricks T, Palmby T, Fu W, Liu Q, Goldberg KB, Kim G, Pazdur R. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Oncologist 2017;22:743-9. [PMID: 28424325 DOI: 10.1634/theoncologist.2017-0087] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 15.2] [Reference Citation Analysis]
361 Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget 2016;7:34341-55. [PMID: 27145284 DOI: 10.18632/oncotarget.9114] [Cited by in Crossref: 143] [Cited by in F6Publishing: 141] [Article Influence: 35.8] [Reference Citation Analysis]
362 Gammelgaard OL, Terp MG, Preiss B, Ditzel HJ. Human cancer evolution in the context of a human immune system in mice. Mol Oncol 2018;12:1797-810. [PMID: 30120895 DOI: 10.1002/1878-0261.12374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
363 Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, Kudo M, Ito A, Nakagawa K. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529-536. [PMID: 28317087 DOI: 10.1007/s10637-017-0453-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 13.4] [Reference Citation Analysis]
364 Nagaya T, Nakamura Y, Sato K, Harada T, Choyke PL, Hodge JW, Schlom J, Kobayashi H. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget. 2017;8:8807-8817. [PMID: 27716622 DOI: 10.18632/oncotarget.12410] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
365 Oyama Y, Onishi H, Koga S, Murahashi M, Ichimiya S, Nakayama K, Fujimura A, Kawamoto M, Imaizumi A, Umebayashi M, Ohuchida K, Morisaki T, Nakamura M. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. J Immunother 2020;43:121-33. [PMID: 31834207 DOI: 10.1097/CJI.0000000000000305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
366 Sui X, Ma J, Han W, Wang X, Fang Y, Li D, Pan H, Zhang L. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget 2015;6:19393-404. [PMID: 26305724 DOI: 10.18632/oncotarget.5107] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
367 Sethakorn N, O'Donnell PH. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma. BJU Int 2016;118:681-91. [PMID: 27271022 DOI: 10.1111/bju.13552] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
368 Redelman-Sidi G, Michielin O, Cervera C, Ribi C, Aguado JM, Fernández-Ruiz M, Manuel O. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect 2018;24 Suppl 2:S95-S107. [PMID: 29427804 DOI: 10.1016/j.cmi.2018.01.030] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
369 Lombard AP, Mudryj M. The emerging role of the androgen receptor in bladder cancer. Endocr Relat Cancer 2015;22:R265-77. [PMID: 26229034 DOI: 10.1530/ERC-15-0209] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
370 Teo MY, Rosenberg JE. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. Urologic Clinics of North America 2018;45:287-95. [DOI: 10.1016/j.ucl.2017.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
371 Peranzoni E, Ingangi V, Masetto E, Pinton L, Marigo I. Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. Front Immunol 2020;11:1590. [PMID: 32793228 DOI: 10.3389/fimmu.2020.01590] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
372 Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol 2018;15:615-25. [PMID: 29991725 DOI: 10.1038/s41585-018-0055-4] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 34.7] [Reference Citation Analysis]
373 Bay ML, Unterrainer N, Stagaard R, Pedersen KS, Schauer T, Staffeldt MM, Christensen JF, Hojman P, Pedersen BK, Gehl J. Voluntary wheel running can lead to modulation of immune checkpoint molecule expression. Acta Oncol 2020;59:1447-54. [PMID: 32935602 DOI: 10.1080/0284186X.2020.1817550] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
374 Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM. The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Rev Anticancer Ther 2016;16:255-71. [PMID: 26781169 DOI: 10.1586/14737140.2016.1143777] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
375 Tessier-Cloutier B, Cai E, Schaeffer DF. Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. Diagn Pathol 2019;14:62. [PMID: 31221175 DOI: 10.1186/s13000-019-0843-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
376 Rouanne M, Roumiguié M, Houédé N, Masson-Lecomte A, Colin P, Pignot G, Larré S, Xylinas E, Rouprêt M, Neuzillet Y. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J Urol 2018;36:1727-40. [PMID: 29855698 DOI: 10.1007/s00345-018-2332-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
377 Vick E, Mahadevan D. Programming the immune checkpoint to treat hematologic malignancies. Expert Opin Investig Drugs 2016;25:755-70. [PMID: 27070269 DOI: 10.1080/13543784.2016.1175433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
378 Farina MS, Lundgren KT, Bellmunt J. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs 2017;77:1077-89. [PMID: 28493171 DOI: 10.1007/s40265-017-0748-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
379 Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6:37. [PMID: 29747688 DOI: 10.1186/s40425-018-0346-6] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 21.5] [Reference Citation Analysis]
380 Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev 2018;64:11-20. [PMID: 29407369 DOI: 10.1016/j.ctrv.2017.12.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 12.0] [Reference Citation Analysis]
381 Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, Neesse A. Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews 2020;100:1707-51. [DOI: 10.1152/physrev.00042.2019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
382 Chaudhri A, Xiao Y, Klee AN, Wang X, Zhu B, Freeman GJ. PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface. Cancer Immunol Res 2018;6:921-9. [PMID: 29871885 DOI: 10.1158/2326-6066.CIR-17-0316] [Cited by in Crossref: 61] [Cited by in F6Publishing: 40] [Article Influence: 15.3] [Reference Citation Analysis]
383 Gartrell BA, He T, Sharma J, Sonpavde G. Update of systemic immunotherapy for advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 2017;35:678-86. [DOI: 10.1016/j.urolonc.2017.09.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
384 Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, Mohile SG, Fung C. Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging 2015;10:939-49. [PMID: 26089655 DOI: 10.2147/CIA.S74322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 19] [Article Influence: 0.4] [Reference Citation Analysis]
385 Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature 2017;541:321-30. [DOI: 10.1038/nature21349] [Reference Citation Analysis]
386 Pagès F, Granier C, Kirilovsky A, Elsissy C, Tartour E. Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices. Bull Cancer 2016;103 Suppl 1:S151-9. [PMID: 28057179 DOI: 10.1016/S0007-4551(16)30373-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
387 Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS, Christensen JG. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol Immunother 2018;67:381-92. [PMID: 29124315 DOI: 10.1007/s00262-017-2091-y] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 10.8] [Reference Citation Analysis]
388 Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol 2020;25:790-800. [PMID: 31900651 DOI: 10.1007/s10147-019-01588-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 22.0] [Reference Citation Analysis]
389 Sanaei M, Pourbagheri-sigaroodi A, Kaveh V, Sheikholeslami SA, Salari S, Bashash D. The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology 2021;157:103160. [DOI: 10.1016/j.critrevonc.2020.103160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
390 Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol 2017;71:281-9. [PMID: 27726966 DOI: 10.1016/j.eururo.2016.09.042] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
391 Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, Nagano H, Nomura K, Okumura S, Shibutani T, Ishikawa Y. WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer 2016;243:21-8. [PMID: 27721121 DOI: 10.1016/j.lungcan.2016.09.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
392 Cao J, Brouwer NJ, Richards KE, Marinkovic M, van Duinen S, Hurkmans D, Verdegaal EME, Jordanova ES, Jager MJ. PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget 2017;8:54722-34. [PMID: 28903377 DOI: 10.18632/oncotarget.18039] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
393 Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY. Imaging Biomarkers in Immunotherapy. Biomark Cancer 2016;8:1-13. [PMID: 26949344 DOI: 10.4137/BIC.S31805] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
394 Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321-330. [PMID: 28102259 DOI: 10.1038/nature21349] [Cited by in Crossref: 1633] [Cited by in F6Publishing: 1567] [Article Influence: 326.6] [Reference Citation Analysis]
395 [DOI: 10.1101/669812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
396 Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 2017;66:551-64. [DOI: 10.1007/s00262-017-1954-6] [Cited by in Crossref: 162] [Cited by in F6Publishing: 163] [Article Influence: 32.4] [Reference Citation Analysis]
397 Callahan MK, Postow MA, Wolchok JD. Targeting T Cell Co-receptors for Cancer Therapy. Immunity 2016;44:1069-78. [PMID: 27192570 DOI: 10.1016/j.immuni.2016.04.023] [Cited by in Crossref: 271] [Cited by in F6Publishing: 261] [Article Influence: 54.2] [Reference Citation Analysis]
398 Xie QK, Chen P, Hu WM, Sun P, He WZ, Jiang C, Kong PF, Liu SS, Chen HT, Yang YZ, Wang D, Yang L, Xia LP. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. J Transl Med 2018;16:273. [PMID: 30286769 DOI: 10.1186/s12967-018-1638-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
399 Nakamura K, Kiniwa Y, Okuyama R. CCL5 production by fibroblasts through a local renin-angiotensin system in malignant melanoma affects tumor immune responses. J Cancer Res Clin Oncol 2021;147:1993-2001. [PMID: 33770254 DOI: 10.1007/s00432-021-03612-8] [Reference Citation Analysis]
400 Iida K, Kawai N, Naiki T, Etani T, Ando R, Nagai T, Sugiyama Y, Naiki-Ito A, Nishio H, Okada A, Kohri K, Yasui T. A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review. Case Rep Oncol 2015;8:530-5. [PMID: 26668577 DOI: 10.1159/000442347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
401 Purrington KS, Visscher DW, Wang C, Yannoukakos D, Hamann U, Nevanlinna H, Cox A, Giles GG, Eckel-Passow JE, Lakis S, Kotoula V, Fountzilas G, Kabisch M, Rüdiger T, Heikkilä P, Blomqvist C, Cross SS, Southey MC, Olson JE, Gilbert J, Deming-Halverson S, Kosma VM, Clarke C, Scott R, Jones JL, Zheng W, Mannermaa A, Eccles DM, Vachon CM, Couch FJ; Jane Carpenter for ABCTC Investigators. Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. Breast Cancer Res Treat 2016;157:117-31. [PMID: 27083182 DOI: 10.1007/s10549-016-3775-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
402 Stjepanovic N, Velazquez-martin J, Bedard P. Ocular toxicities of MEK inhibitors and other targeted therapies. Annals of Oncology 2016;27:998-1005. [DOI: 10.1093/annonc/mdw100] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
403 Fa'ak F, Vanegas D, Osei KM. A Case Report of Atezolizumab Induced Tumor Lysis Syndrome. Am J Case Rep 2019;20:785-9. [PMID: 31160547 DOI: 10.12659/AJCR.915351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
404 Tawfik O, Kimler BF, Karnik T, Shehata P. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells. Hum Pathol 2018;80:170-8. [PMID: 29936058 DOI: 10.1016/j.humpath.2018.06.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
405 Inamura K, Yokouchi Y, Sakakibara R, Kobayashi M, Subat S, Ninomiya H, Nagano H, Nomura K, Okumura S, Ishikawa Y. Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. Jpn J Clin Oncol 2016;46:935-41. [DOI: 10.1093/jjco/hyw087] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
406 Lee DH, Jeong JY, Song W. Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study. Onco Targets Ther 2021;14:845-55. [PMID: 33574678 DOI: 10.2147/OTT.S291327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
407 Sharma P. Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer J 2016;22:68-72. [PMID: 27111900 DOI: 10.1097/PPO.0000000000000185] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
408 Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 2019;75:423-32. [PMID: 30213523 DOI: 10.1016/j.eururo.2018.08.027] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 25.0] [Reference Citation Analysis]
409 He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, Zhou C, Hirsch FR. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. 2016;107:1193-1197. [PMID: 27297395 DOI: 10.1111/cas.12986] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 14.2] [Reference Citation Analysis]
410 Chang K, Qu Y, Dai B, Zhao JY, Gan H, Shi G, Zhu Y, Shen Y, Zhu Y, Zhang H, Ye D. PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. Sci Rep 2017;7:2074. [PMID: 28522811 DOI: 10.1038/s41598-017-02005-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
411 Boström MM, Irjala H, Mirtti T, Taimen P, Kauko T, Ålgars A, Jalkanen S, Boström PJ. Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer. PLoS One 2015;10:e0133552. [PMID: 26197470 DOI: 10.1371/journal.pone.0133552] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
412 Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ, Ryu SE, Son JY, Lee JU, Heo YS. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun 2016;7:13354. [PMID: 27796306 DOI: 10.1038/ncomms13354] [Cited by in Crossref: 135] [Cited by in F6Publishing: 121] [Article Influence: 22.5] [Reference Citation Analysis]
413 Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight 2016;1:e86014. [PMID: 27182556 DOI: 10.1172/jci.insight.86014] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
414 Hurwitz MD. Hyperthermia and immunotherapy: clinical opportunities. Int J Hyperthermia 2019;36:4-9. [PMID: 31795827 DOI: 10.1080/02656736.2019.1653499] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
415 Chang YL, Yang CY, Huang YL, Wu CT, Yang PC. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget 2017;8:18021-30. [PMID: 28152514 DOI: 10.18632/oncotarget.14935] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
416 Kojima T, Kawai K, Miyazaki J, Nishiyama H. Biomarkers for precision medicine in bladder cancer. Int J Clin Oncol 2017;22:207-13. [PMID: 27896485 DOI: 10.1007/s10147-016-1068-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
417 Wei Y, Xiao X, Lao XM, Zheng L, Kuang DM. Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cell Mol Life Sci 2021;78:867-87. [PMID: 32940722 DOI: 10.1007/s00018-020-03637-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
418 Rad Pour S, Pico de Coaña Y, Demorentin XM, Melief J, Thimma M, Wolodarski M, Gomez-Cabrero D, Hansson J, Kiessling R, Tegner J. Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood. J Immunother Cancer 2021;9:e002171. [PMID: 33963011 DOI: 10.1136/jitc-2020-002171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2020;17:75-90. [PMID: 31548600 DOI: 10.1038/s41571-019-0266-5] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 25.3] [Reference Citation Analysis]
420 Agrawal L, Engel KB, Greytak SR, Moore HM. Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Semin Cancer Biol 2018;52:26-38. [PMID: 29258857 DOI: 10.1016/j.semcancer.2017.12.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
421 Botti G, Fratangelo F, Cerrone M, Liguori G, Cantile M, Anniciello AM, Scala S, D'Alterio C, Trimarco C, Ianaro A, Cirino G, Caracò C, Colombino M, Palmieri G, Pepe S, Ascierto PA, Sabbatino F, Scognamiglio G. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. J Transl Med 2017;15:46. [PMID: 28231855 DOI: 10.1186/s12967-017-1150-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 10.0] [Reference Citation Analysis]
422 Isakov N. Cancer immunotherapy by targeting immune checkpoint receptors. World J Immunol 2018; 8(1): 1-11 [DOI: 10.5411/wji.v8.i1.1] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Phan TG, Long GV, Scolyer RA. Multiple checkpoints on the long road towards cancer immunotherapy. Immunol Cell Biol 2015;93:323-5. [DOI: 10.1038/icb.2015.12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
424 Shao IH, Chang YH, Pang ST. Recent advances in upper tract urothelial carcinomas: From bench to clinics. Int J Urol 2019;26:148-59. [PMID: 30372791 DOI: 10.1111/iju.13826] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
425 Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205-214. [PMID: 25860605 DOI: 10.1016/j.cell.2015.03.030] [Cited by in Crossref: 1194] [Cited by in F6Publishing: 1121] [Article Influence: 170.6] [Reference Citation Analysis]
426 Zhang H, Deng M, Lin P, Liu J, Liu C, Strohl WR, Wang S, Ho M. Frontiers and Opportunities: Highlights of the 2nd Annual Conference of the Chinese Antibody Society. Antib Ther 2018;1:65-74. [PMID: 30406214 DOI: 10.1093/abt/tby009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
427 Martinez Rodriguez RH, Buisan Rueda O, Ibarz L. Bladder cancer: Present and future. Med Clin (Barc) 2017;149:449-55. [PMID: 28736063 DOI: 10.1016/j.medcli.2017.06.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
428 Lu YC, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol 2016;28:22-7. [PMID: 26653770 DOI: 10.1016/j.smim.2015.11.002] [Cited by in Crossref: 126] [Cited by in F6Publishing: 122] [Article Influence: 18.0] [Reference Citation Analysis]
429 Ulisse S, Tuccilli C, Sorrenti S, Antonelli A, Fallahi P, D'Armiento E, Catania A, Tartaglia F, Amabile MI, Giacomelli L, Metere A, Cornacchini N, Pironi D, Carbotta G, Vergine M, Monti M, Baldini E. PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. Int J Mol Sci 2019;20:E1405. [PMID: 30897754 DOI: 10.3390/ijms20061405] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
430 Burgess EF, Livasy C, Hartman A, Robinson MM, Symanowski J, Naso C, Doherty S, Guerrieri R, Riggs S, Grigg CM, Clark PE, Raghavan D. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urol Oncol 2019;37:299.e19-25. [PMID: 30660491 DOI: 10.1016/j.urolonc.2019.01.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
431 Sonpavde G, Gordetsky JB, Lockhart ME, Nix JW. Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never? J Clin Oncol 2016;34:780-5. [PMID: 26786922 DOI: 10.1200/JCO.2015.65.4442] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
432 Suekane S, Ueda K, Nishihara K, Sasada T, Yamashita T, Koga N, Yutani S, Shichijo S, Itoh K, Igawa T, Noguchi M. Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma. Cancer Sci 2017;108:2430-7. [PMID: 28940789 DOI: 10.1111/cas.13404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
433 Delcourt C, Gemival P, Nouhaud FX, Gobet F, Gillibert A, Ferlicot S, Sabourin JC, Irani J, Pfister C. Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). World J Urol 2020;38:1517-24. [DOI: 10.1007/s00345-019-02896-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
434 Li X, Wang Y, Li X, Feng G, Hu S, Bai Y. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC. Front Immunol 2021;12:638763. [PMID: 34305884 DOI: 10.3389/fimmu.2021.638763] [Reference Citation Analysis]
435 Xie J, Fu L, Jin L. Immunotherapy of gastric cancer: Past, future perspective and challenges. Pathol Res Pract 2021;218:153322. [PMID: 33422778 DOI: 10.1016/j.prp.2020.153322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
436 Sloan EA, Ring KL, Willis BC, Modesitt SC, Mills AM. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. Am J Surg Pathol 2017;41:326-33. [PMID: 27984238 DOI: 10.1097/PAS.0000000000000783] [Cited by in Crossref: 68] [Cited by in F6Publishing: 28] [Article Influence: 13.6] [Reference Citation Analysis]
437 Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, Smith JJ, Garcia-Aguilar J, Sadot E, Ntiamoah P, Markowitz AJ, Shike M, Stadler ZK, Vakiani E, Klimstra DS, Shia J. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol. 2016;29:1433-1442. [PMID: 27443512 DOI: 10.1038/modpathol.2016.139] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 14.2] [Reference Citation Analysis]
438 Mo RJ, Han ZD, Liang YK, Ye JH, Wu SL, Lin SX, Zhang YQ, Song SD, Jiang FN, Zhong WD, Wu CL. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer. Int J Cancer 2019;144:3099-110. [PMID: 30537104 DOI: 10.1002/ijc.32061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
439 Park JE, Kim SE, Keam B, Park HR, Kim S, Kim M, Kim TM, Doh J, Kim DW, Heo DS. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. J Immunother Cancer 2020;8:e000873. [PMID: 32830112 DOI: 10.1136/jitc-2020-000873] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
440 Macek Jilkova Z, Aspord C, Decaens T. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers (Basel) 2019;11:E1554. [PMID: 31615069 DOI: 10.3390/cancers11101554] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
441 Shklovskaya E, Rizos H. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. Int J Mol Sci 2021;22:6741. [PMID: 34201655 DOI: 10.3390/ijms22136741] [Reference Citation Analysis]
442 Kong YY, Fuchsberger M, Plebanski M, Apostolopoulos V. Alteration of early dendritic cell activation by cancer cell lines predisposes immunosuppression, which cannot be reversed by TLR4 stimulation. Acta Biochim Biophys Sin (Shanghai) 2016;48:1101-11. [PMID: 27797716 DOI: 10.1093/abbs/gmw102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
443 Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P, Galliverti G, Swartz MA, Hubbell JA. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med 2017;9:eaan0401. [PMID: 29118259 DOI: 10.1126/scitranslmed.aan0401] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 19.8] [Reference Citation Analysis]
444 Humphries MP, Hynes S, Bingham V, Cougot D, James J, Patel-Socha F, Parkes EE, Blayney JK, O'Rorke MA, Irwin GW, McArt DG, Kennedy RD, Mullan PB, McQuaid S, Salto-Tellez M, Buckley NE. Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. J Oncol 2018;2018:2937012. [PMID: 30651729 DOI: 10.1155/2018/2937012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
445 Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32:147-153. [PMID: 30171197 DOI: 10.1038/s41379-018-0118-3] [Cited by in Crossref: 179] [Cited by in F6Publishing: 164] [Article Influence: 44.8] [Reference Citation Analysis]
446 Kamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor J, Williams SB, Quale DZ, Rosenberg JE. Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer 2016;2:203-13. [PMID: 27376139 DOI: 10.3233/BLC-169007] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
447 Karnik T, Kimler BF, Fan F, Tawfik O. PD-L1 in breast cancer: comparative analysis of 3 different antibodies. Human Pathology 2018;72:28-34. [DOI: 10.1016/j.humpath.2017.08.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
448 Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, Fassò M, O'Hear C, Vogelzang NJ. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncol 2018;4:537-44. [PMID: 29423515 DOI: 10.1001/jamaoncol.2017.5440] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 20.7] [Reference Citation Analysis]
449 Kansy BA, Shayan G, Jie HB, Gibson SP, Lei YL, Brandau S, Lang S, Schmitt NC, Ding F, Lin Y, Ferris RL. T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. Oncoimmunology 2018;7:e1494112. [PMID: 30377562 DOI: 10.1080/2162402X.2018.1494112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
450 Foller S, Oppel-heuchel H, Grimm M. Tumorassessment bei Immun-Checkpoint-Inhibitor-Therapie: Tumoransprechen, Progression und Pseudoprogression. Urologe 2018;57:1316-25. [DOI: 10.1007/s00120-018-0788-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
451 Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer 2016;4:3. [PMID: 26788324 DOI: 10.1186/s40425-016-0107-3] [Cited by in Crossref: 126] [Cited by in F6Publishing: 115] [Article Influence: 21.0] [Reference Citation Analysis]
452 Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, Odunsi K, Segal BH, Dy GK, Ernstoff MS, Ito F. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun 2021;12:1402. [PMID: 33658501 DOI: 10.1038/s41467-021-21619-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
453 Sun WY, Lee YK, Koo JS. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med 2016;14:173. [PMID: 27286842 DOI: 10.1186/s12967-016-0925-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 10.5] [Reference Citation Analysis]
454 Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res 2017;27:96-108. [PMID: 27981969 DOI: 10.1038/cr.2016.149] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 27.3] [Reference Citation Analysis]
455 Sun Z, Mao A, Wang Y, Zhao Y, Chen J, Xu P, Miao C. Treatment with anti-programmed cell death 1 (PD-1) antibody restored postoperative CD8+ T cell dysfunction by surgical stress. Biomedicine & Pharmacotherapy 2017;89:1235-41. [DOI: 10.1016/j.biopha.2017.03.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
456 Guo S, Contratto M, Miller G, Leichman L, Wu J. Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World J Clin Oncol 2017; 8(3): 230-240 [PMID: 28638792 DOI: 10.5306/wjco.v8.i3.230] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
457 Schoppy DW, Sunwoo JB. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Hematol Oncol Clin North Am 2015;29:1033-43. [PMID: 26568546 DOI: 10.1016/j.hoc.2015.07.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
458 Qu F, Ye J, Pan X, Wang J, Gan S, Chu C, Chu J, Zhang X, Liu M, He H, Cui X. MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. J Drug Target 2019;27:67-74. [PMID: 30183478 DOI: 10.1080/1061186X.2018.1479755] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
459 Karin M. New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precis Clin Med. 2018;1:21-28. [PMID: 30687560 DOI: 10.1093/pcmedi/pby005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
460 Oba A, Shimada S, Akiyama Y, Nishikawaji T, Mogushi K, Ito H, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Asahara H, Kaida A, Miura M, Tanabe M, Tanaka S. ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. Journal of Hepatology 2017;66:942-51. [DOI: 10.1016/j.jhep.2016.12.026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
461 Kim YS, Lee SI, Park SH, Park S, Hwang IG, Lee SC, Sun JM, Lee J, Lim HY. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. Clin Genitourin Cancer 2016;14:76-81. [PMID: 26454620 DOI: 10.1016/j.clgc.2015.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
462 Song M, Chen X, Wang L, Zhang Y. Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chin J Cancer Res 2018;30:157-72. [PMID: 29861603 DOI: 10.21147/j.issn.1000-9604.2018.02.01] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
463 Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 2015;7:967-80. [PMID: 26310908 DOI: 10.2217/imt.15.65] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
464 Giraldo NA, Becht E, Vano Y, Sautès-fridman C, Fridman WH. The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch 2015;467:127-35. [DOI: 10.1007/s00428-015-1787-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
465 Laserna A, Tummala S, Patel N, El Hamouda DEM, Gutiérrez C. Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature. SAGE Open Med Case Rep 2018;6:2050313X18792422. [PMID: 30116528 DOI: 10.1177/2050313X18792422] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
466 Nowicki TS, Anderson JL, Federman N. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatr Res 2016;79:371-7. [PMID: 26595537 DOI: 10.1038/pr.2015.246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
467 Duan XC, Peng LY, Yao X, Xu MQ, Li H, Zhang SQ, Li ZY, Wang JR, Feng ZH, Wang GX, Liao A, Chen Y, Zhang X. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death. Drug Deliv 2021;28:800-13. [PMID: 33866918 DOI: 10.1080/10717544.2021.1909180] [Reference Citation Analysis]
468 Heidegger S, Kreppel D, Bscheider M, Stritzke F, Nedelko T, Wintges A, Bek S, Fischer JC, Graalmann T, Kalinke U, Bassermann F, Haas T, Poeck H. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade. EBioMedicine 2019;41:146-55. [PMID: 30852164 DOI: 10.1016/j.ebiom.2019.02.056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
469 Alsina M, Moehler M, Hierro C, Guardeño R, Tabernero J. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Target Oncol 2016;11:469-77. [PMID: 26880697 DOI: 10.1007/s11523-016-0421-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
470 Schwamborn K, Ammann JU, Knüchel R, Hartmann A, Baretton G, Lasitschka F, Schirmacher P, Braunschweig T, Tauber R, Erlmeier F, Hieke-Schulz S, Weichert W. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Arch 2019;475:599-608. [PMID: 31267201 DOI: 10.1007/s00428-019-02610-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
471 Sood A, Cole D, Abdollah F, Eilender B, Roumayah Z, Deebajah M, Dabaja A, Alanee S. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. Curr Urol Rep 2018;19:68. [PMID: 29971696 DOI: 10.1007/s11934-018-0819-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
472 Wurz GT, Kao CJ, DeGregorio MW. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 2016;8:4-31. [PMID: 26753003 DOI: 10.1177/1758834015615514] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
473 Gong K, Gong ZJ, Lu PX, Ni XL, Shen S, Liu H, Wang JW, Zhang DX, Liu HB, Suo T. PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma. Biochem Biophys Res Commun 2019;516:983-90. [PMID: 31272718 DOI: 10.1016/j.bbrc.2019.06.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
474 Billon E, Finetti P, Bertucci A, Niccoli P, Birnbaum D, Mamessier E, Bertucci F. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. Oncoimmunology 2019;8:e1655362. [PMID: 31646101 DOI: 10.1080/2162402X.2019.1655362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
475 Dong L, Chen C, Zhang Y, Guo P, Wang Z, Li J, Liu Y, Liu J, Chang R, Li Y, Liang G, Lai W, Sun M, Dougherty U, Bissonnette MB, Wang H, Shen L, Xu MM, Han D. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. Cancer Cell 2021;39:945-957.e10. [PMID: 34019807 DOI: 10.1016/j.ccell.2021.04.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
476 Sotelo M, Alonso-Gordoa T, Gajate P, Gallardo E, Morales-Barrera R, Pérez-Gracia JL, Puente J, Sánchez P, Castellano D, Durán I. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. Clin Transl Oncol 2021;23:882-91. [PMID: 32897497 DOI: 10.1007/s12094-020-02482-9] [Reference Citation Analysis]
477 Chang X, Xia C. Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP10025–33 peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma. Biochemical and Biophysical Research Communications 2015;468:46-52. [DOI: 10.1016/j.bbrc.2015.10.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
478 Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128. [PMID: 25765070 DOI: 10.1126/science.aaa1348] [Cited by in Crossref: 4283] [Cited by in F6Publishing: 4119] [Article Influence: 611.9] [Reference Citation Analysis]
479 Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol 2018;15:92-111. [PMID: 29133939 DOI: 10.1038/nrurol.2017.179] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 14.2] [Reference Citation Analysis]
480 Mo Q, Nikolos F, Chen F, Tramel Z, Lee YC, Hayashi K, Xiao J, Shen J, Chan KS. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. J Natl Cancer Inst 2018;110:448-59. [PMID: 29342309 DOI: 10.1093/jnci/djx243] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 17.3] [Reference Citation Analysis]
481 García-Díez I, Hernández-Ruiz E, Andrades E, Gimeno J, Ferrándiz-Pulido C, Yébenes M, García-Patos V, Pujol RM, Hernández-Muñoz I, Toll A. PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases. Am J Dermatopathol 2018;40:647-54. [PMID: 29742559 DOI: 10.1097/DAD.0000000000001164] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
482 Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016;7:1486-1499. [PMID: 26625204 DOI: 10.18632/oncotarget.6429] [Cited by in Crossref: 142] [Cited by in F6Publishing: 143] [Article Influence: 23.7] [Reference Citation Analysis]
483 Pavlovic K, Tristán-Manzano M, Maldonado-Pérez N, Cortijo-Gutierrez M, Sánchez-Hernández S, Justicia-Lirio P, Carmona MD, Herrera C, Martin F, Benabdellah K. Using Gene Editing Approaches to Fine-Tune the Immune System. Front Immunol 2020;11:570672. [PMID: 33117361 DOI: 10.3389/fimmu.2020.570672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
484 Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS. FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model. Int J Cancer 2019;144:345-54. [PMID: 30259976 DOI: 10.1002/ijc.31899] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
485 Nguyen DP, Thalmann GN. Contemporary update on neoadjuvant therapy for bladder cancer. Nat Rev Urol 2017;14:348-58. [PMID: 28290459 DOI: 10.1038/nrurol.2017.30] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
486 Zhang C, Shen L, Qi F, Wang J, Luo J. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma. J Cell Physiol 2020;235:3849-63. [PMID: 31596511 DOI: 10.1002/jcp.29279] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
487 Zhao T, Li C, Wu Y, Li B, Zhang B. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. PLoS One. 2017;12:e0176822. [PMID: 28453554 DOI: 10.1371/journal.pone.0176822] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
488 Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell 2020;181:1612-1625.e13. [PMID: 32497499 DOI: 10.1016/j.cell.2020.05.017] [Cited by in Crossref: 97] [Cited by in F6Publishing: 78] [Article Influence: 48.5] [Reference Citation Analysis]
489 Rzhevskiy A, Kapitannikova A, Malinina P, Volovetsky A, Aboulkheyr Es H, Kulasinghe A, Thiery JP, Maslennikova A, Zvyagin AV, Ebrahimi Warkiani M. Emerging role of circulating tumor cells in immunotherapy. Theranostics 2021;11:8057-75. [PMID: 34335980 DOI: 10.7150/thno.59677] [Reference Citation Analysis]
490 Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, Montironi R, Santini D, Cheng L, Martignoni G, Cascinu S, Tortora G. The route to personalized medicine in bladder cancer: where do we stand? Targ Oncol 2015;10:325-36. [DOI: 10.1007/s11523-015-0357-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
491 Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol 2015;42:640-55. [PMID: 26320067 DOI: 10.1053/j.seminoncol.2015.05.014] [Cited by in Crossref: 114] [Cited by in F6Publishing: 109] [Article Influence: 16.3] [Reference Citation Analysis]
492 Xu Z, Huang B, Zhang Q, He X, Wei H, Zhang D. NOTCH1 regulates the proliferation and migration of bladder cancer cells by cooperating with long non-coding RNA HCG18 and microRNA-34c-5p. J Cell Biochem 2019;120:6596-604. [PMID: 30426533 DOI: 10.1002/jcb.27954] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
493 Buttigliero C, Tucci M, Vignani F, Scagliotti GV, Di Maio M. Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treat Rev 2017;54:1-9. [PMID: 28135623 DOI: 10.1016/j.ctrv.2017.01.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
494 Lee EY, Kulkarni RP. Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Rev Mol Diagn 2019;19:895-904. [PMID: 31469965 DOI: 10.1080/14737159.2019.1659728] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
495 Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384-3391. [PMID: 26325035 DOI: 10.1172/jci80011] [Cited by in Crossref: 665] [Cited by in F6Publishing: 427] [Article Influence: 95.0] [Reference Citation Analysis]
496 Wu X, Lan X, Hu W, Zhang W, Lai X, Xu S, Li J, Qiu W, Wang W, Xiao J, Wang F, Ding Y, Liang L. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. Cancer Immunol Immunother 2021. [PMID: 33818637 DOI: 10.1007/s00262-021-02931-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
497 Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, Blank CU, Xiao Y, Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 2017;549:106-10. [PMID: 28813410 DOI: 10.1038/nature23669] [Cited by in Crossref: 241] [Cited by in F6Publishing: 240] [Article Influence: 48.2] [Reference Citation Analysis]
498 Guleria P, Husain N, Shukla S, Kumar S, Parshad R, Jain D. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature. Ann Diagn Pathol 2018;34:135-41. [PMID: 29661720 DOI: 10.1016/j.anndiagpath.2018.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
499 Hegde UP, Mukherji B. Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunol Immunother 2017;66:1113-21. [PMID: 28497159 DOI: 10.1007/s00262-017-2007-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
500 Vau N, Volavsek M, Blanca A, Montironi R, Raspollini MR, Massari F, Cheng M, Scarpelli M, Lopez-beltran A. Prospects for precision therapy of bladder urothelial carcinoma. Expert Review of Precision Medicine and Drug Development 2017;2:261-74. [DOI: 10.1080/23808993.2017.1389273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
501 Messing EM. Checkpoint Inhibitors for Advanced Bladder Cancer. Bladder Cancer 2016;2:473-4. [PMID: 28035330 DOI: 10.3233/BLC-169011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
502 Menis J, Litière S, Tryfonidis K, Golfinopoulos V. The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Ann Transl Med 2016;4:267. [PMID: 27563654 DOI: 10.21037/atm.2016.06.19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
503 Thangarajah F, Morgenstern B, Pahmeyer C, Schiffmann LM, Puppe J, Mallmann P, Hamacher S, Buettner R, Alidousty C, Holz B, Scheel AH, Schultheis AM. Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. J Cancer Res Clin Oncol 2019;145:1651-60. [PMID: 30972492 DOI: 10.1007/s00432-019-02915-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
504 Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, Zhang X, Chang Y, Sun Z, Yu H, Zhang L, Wang X, Wu J, Li Z, Nan F, Tian L, Li W, Young KH. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol 2018;11:15. [PMID: 29386072 DOI: 10.1186/s13045-018-0559-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 19.0] [Reference Citation Analysis]
505 Oh SA, Wu D, Cheung J, Navarro A, Xiong H, Cubas R, Totpal K, Chiu H, Wu Y, Comps-agrar L, Leader AM, Merad M, Roose-germa M, Warming S, Yan M, Kim JM, Rutz S, Mellman I. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer 2020;1:681-91. [DOI: 10.1038/s43018-020-0075-x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 27] [Article Influence: 37.5] [Reference Citation Analysis]
506 Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 2017;5:480-92. [PMID: 28522460 DOI: 10.1158/2326-6066.CIR-16-0329] [Cited by in Crossref: 156] [Cited by in F6Publishing: 109] [Article Influence: 31.2] [Reference Citation Analysis]
507 Font A, Luque R, Villa JC, Domenech M, Vázquez S, Gallardo E, Virizuela JA, Beato C, Morales-Barrera R, Gelabert A, Maciá S, Puente J, Rubio G, Maldonado X, Perez-Valderrama B, Pinto A, Fernández Calvo O, Grande E, Garde-Noguera J, Fernández-Parra E, Arranz JÁ. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). Target Oncol 2019;14:15-32. [PMID: 30694442 DOI: 10.1007/s11523-019-00619-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
508 Zhang Y, Wang T, Tian Y, Zhang C, Ge K, Zhang J, Chang J, Wang H. Gold nanorods-mediated efficient synergistic immunotherapy for detection and inhibition of postoperative tumor recurrence. Acta Pharm Sin B 2021;11:1978-92. [PMID: 34386332 DOI: 10.1016/j.apsb.2021.03.035] [Reference Citation Analysis]
509 Cao JZ, Wu W, Pan JF, Wang HW, Jiang JH, Ma Q. Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation. Front Oncol 2021;11:643413. [PMID: 34109111 DOI: 10.3389/fonc.2021.643413] [Reference Citation Analysis]
510 Lodewijk I, Dueñas M, Rubio C, Munera-Maravilla E, Segovia C, Bernardini A, Teijeira A, Paramio JM, Suárez-Cabrera C. Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. Int J Mol Sci 2018;19:E2514. [PMID: 30149597 DOI: 10.3390/ijms19092514] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
511 Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D. Biomarqueurs prédictifs de l’immunothérapie anti-PD1/PD-L1 dans le cancer broncho-pulmonaire non à petites cellules. Revue de Pneumologie Clinique 2018;74:339-50. [DOI: 10.1016/j.pneumo.2018.09.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
512 Joneja U, Vranic S, Swensen J, Feldman R, Chen W, Kimbrough J, Xiao N, Reddy S, Palazzo J, Gatalica Z. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol 2017;70:255-9. [PMID: 27531819 DOI: 10.1136/jclinpath-2016-203874] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 9.2] [Reference Citation Analysis]
513 Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol 2017;3:e172411. [PMID: 28817753 DOI: 10.1001/jamaoncol.2017.2411] [Cited by in Crossref: 464] [Cited by in F6Publishing: 459] [Article Influence: 92.8] [Reference Citation Analysis]
514 Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, Kwiatkowski DJ, Fargo DC, Mieczkowski PA, Getz G, Gordenin DA. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet 2015;47:1067-72. [PMID: 26258849 DOI: 10.1038/ng.3378] [Cited by in Crossref: 230] [Cited by in F6Publishing: 195] [Article Influence: 32.9] [Reference Citation Analysis]
515 Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, Smylie M, Verma S. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol 2018;25:e373-84. [PMID: 30464687 DOI: 10.3747/co.25.3840] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
516 Wu D, Wei C, Li Y, Yang X, Zhou S. Pyroptosis, a New Breakthrough in Cancer Treatment. Front Oncol 2021;11:698811. [PMID: 34381721 DOI: 10.3389/fonc.2021.698811] [Reference Citation Analysis]
517 Li X, Dai D, Chen B, Tang H, Xie X, Wei W. The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. J Cancer 2018;9:861-71. [PMID: 29581764 DOI: 10.7150/jca.23367] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
518 Abufaraj M, Gust K, Moschini M, Foerster B, Soria F, Mathieu R, Shariat SF. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Transl Androl Urol 2016;5:735-44. [PMID: 27785430 DOI: 10.21037/tau.2016.08.23] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
519 Raghavan D. Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years. Bladder Cancer 2015;1:3-13. [PMID: 30561439 DOI: 10.3233/BLC-150010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
520 He Q, Guo S, Qian Z, Chen X. Development of individualized anti-metastasis strategies by engineering nanomedicines. Chem Soc Rev 2015;44:6258-86. [PMID: 26056688 DOI: 10.1039/c4cs00511b] [Cited by in Crossref: 83] [Cited by in F6Publishing: 16] [Article Influence: 11.9] [Reference Citation Analysis]
521 van Kessel KEM, Zuiverloon TCM, Alberts AR, Boormans JL, Zwarthoff EC. Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol 2015;12:681-94. [DOI: 10.1038/nrurol.2015.231] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
522 Tessarollo NG, Domingues ACM, Antunes F, Luz JCDSD, Rodrigues OA, Cerqueira OLD, Strauss BE. Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy. Cancers (Basel) 2021;13:1863. [PMID: 33919679 DOI: 10.3390/cancers13081863] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
523 Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, Scutti JB, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P. Characterization and Comparison of GITR Expression in Solid Tumors. Clin Cancer Res 2019;25:6501-10. [PMID: 31358539 DOI: 10.1158/1078-0432.CCR-19-0289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
524 Zhou ZQ, Zhao JJ, Pan QZ, Chen CL, Liu Y, Tang Y, Zhu Q, Weng DS, Xia JC. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. J Immunother Cancer 2019;7:228. [PMID: 31455411 DOI: 10.1186/s40425-019-0696-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
525 Rouanne M, Radulescu C, Adam J, Allory Y. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. World J Urol 2021;39:1345-55. [PMID: 33141317 DOI: 10.1007/s00345-020-03498-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
526 Tabayoyong W, Gao J. The emerging role of immunotherapy in advanced urothelial cancers. Curr Opin Oncol 2018;30:172-80. [PMID: 29553950 DOI: 10.1097/CCO.0000000000000445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
527 Serrano P, Hartmann M, Schmitt E, Franco P, Amexis G, Gross J, Mayer-Nicolai C. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clin Pharmacol Ther 2019;105:582-97. [PMID: 29923615 DOI: 10.1002/cpt.1123] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
528 Dong L, Lv H, Li W, Song Z, Li L, Zhou S, Qiu L, Qian Z, Liu X, Feng L, Meng B, Fu K, Wang X, Pan-Hammarström Q, Wang P, Wang X, Zhang H. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget 2016;7:33350-62. [PMID: 27147575 DOI: 10.18632/oncotarget.9061] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
529 Griffiths JI, Wallet P, Pflieger LT, Stenehjem D, Liu X, Cosgrove PA, Leggett NA, McQuerry JA, Shrestha G, Rossetti M, Sunga G, Moos PJ, Adler FR, Chang JT, Sharma S, Bild AH. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A 2020;117:16072-82. [PMID: 32571915 DOI: 10.1073/pnas.1918937117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
530 Buisan O, Orsola A, Areal J, Font A, Oliveira M, Martinez R, Ibarz L. Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2017;15:145-151.e2. [DOI: 10.1016/j.clgc.2016.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
531 Bedke J, Kruck S, Gakis G, Stenzl A, Goebell PJ. Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015;11:1201-8. [PMID: 25912622 DOI: 10.1080/21645515.2015.1016657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
532 Jaafar J, Fernandez E, Alwan H, Philippe J. Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocr Connect 2018;7:R196-211. [PMID: 29739808 DOI: 10.1530/EC-18-0079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
533 Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol. 2019;25:101174. [PMID: 30917934 DOI: 10.1016/j.redox.2019.101174] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 19.0] [Reference Citation Analysis]
534 Mukherji D, Jabbour MN, Saroufim M, Temraz S, Nasr R, Charafeddine M, Assi R, Shamseddine A, Tawil AN. Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker? Clinical Genitourinary Cancer 2016;14:183-7. [DOI: 10.1016/j.clgc.2015.12.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
535 LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol 2018;200:375-83. [PMID: 29311378 DOI: 10.4049/jimmunol.1701044] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 15.8] [Reference Citation Analysis]
536 Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, Alshalalfa M, Glavaris S, Simons BW, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis ES, Schaeffer EM, Drake CG, Feng F, Ross AE. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis 2017;20:28-35. [PMID: 27801901 DOI: 10.1038/pcan.2016.49] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 10.3] [Reference Citation Analysis]
537 Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer 2017;24:111-20. [PMID: 26942414 DOI: 10.1007/s12282-016-0682-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
538 McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fassò M, Wang YV. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol. 2016;34:833-842. [PMID: 26755520 DOI: 10.1200/jco.2015.63.7421] [Cited by in Crossref: 356] [Cited by in F6Publishing: 191] [Article Influence: 59.3] [Reference Citation Analysis]
539 Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med 2015;7:280sr1-280sr1. [DOI: 10.1126/scitranslmed.3010274] [Cited by in Crossref: 110] [Cited by in F6Publishing: 100] [Article Influence: 15.7] [Reference Citation Analysis]
540 Economopoulou P, Kotsantis I, Psyrri A. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. Curr Treat Options Oncol. 2016;17:40. [PMID: 27315066 DOI: 10.1007/s11864-016-0419-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
541 Davarpanah NN, Yuno A, Trepel JB, Apolo AB. Immunotherapy: a new treatment paradigm in bladder cancer. Curr Opin Oncol 2017;29:184-95. [PMID: 28306559 DOI: 10.1097/CCO.0000000000000366] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
542 Chen Y, Wang X, Deng X, Zhang Y, Liao R, Li Y, Yang H, Chen K. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma. Front Immunol 2021;12:676922. [PMID: 34335575 DOI: 10.3389/fimmu.2021.676922] [Reference Citation Analysis]
543 Liu Z, Zhao Y, Fang J, Cui R, Xiao Y, Xu Q. SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget 2017;8:53518-30. [PMID: 28881828 DOI: 10.18632/oncotarget.18591] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
544 Coleman N, Ameratunga M, Lopez J. Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. Clin Med Insights Oncol 2018;12:1179554918759079. [PMID: 29511362 DOI: 10.1177/1179554918759079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
545 Chen G, Yang Z, Eshleman JR, Netto GJ, Lin MT. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. Biomed Res Int 2016;2016:9850690. [PMID: 27699178 DOI: 10.1155/2016/9850690] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
546 González Trotter DE, Meng X, McQuade P, Rubins D, Klimas M, Zeng Z, Connolly BM, Miller PJ, O'Malley SS, Lin SA, Getty KL, Fayadat-Dilman L, Liang L, Wahlberg E, Widmark O, Ekblad C, Frejd FY, Hostetler ED, Evelhoch JL. In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET. J Nucl Med 2017;58:1852-7. [PMID: 28588151 DOI: 10.2967/jnumed.117.191718] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
547 Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf) 2016;85:331-9. [PMID: 26998595 DOI: 10.1111/cen.13063] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 21.0] [Reference Citation Analysis]
548 Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017;35:2781-9. [PMID: 28609226 DOI: 10.1200/JCO.2016.71.9476] [Cited by in Crossref: 182] [Cited by in F6Publishing: 118] [Article Influence: 36.4] [Reference Citation Analysis]
549 Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Dömling A, Dubin G, Holak TA. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget 2016;7:30323-35. [PMID: 27083005 DOI: 10.18632/oncotarget.8730] [Cited by in Crossref: 146] [Cited by in F6Publishing: 146] [Article Influence: 29.2] [Reference Citation Analysis]
550 Dong A, Zhao Y, Li Z, Hu H. PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer? J Gene Med 2021;23:e3294. [PMID: 33171529 DOI: 10.1002/jgm.3294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
551 Sehgal K, Costa DB, Rangachari D. Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? Front Oncol 2020;10:1193. [PMID: 32714874 DOI: 10.3389/fonc.2020.01193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
552 Ottenhof SR, Djajadiningrat RS, de Jong J, Thygesen HH, Horenblas S, Jordanova ES. Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status. J Urol 2017;197:690-7. [PMID: 27697578 DOI: 10.1016/j.juro.2016.09.088] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
553 Shao Y, Zhu W, Da J, Xu M, Wang Y, Zhou J, Wang Z. Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer. Onco Targets Ther 2017;10:2675-83. [PMID: 28579805 DOI: 10.2147/OTT.S130653] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
554 Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer 2020;8:e001673. [PMID: 33303579 DOI: 10.1136/jitc-2020-001673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
555 Akyala AI, Verhaar AP, Peppelenbosch MP. Immune checkpoint inhibition in gastric cancer: A systematic review. Journal of Cellular Immunotherapy 2018;4:49-55. [DOI: 10.1016/j.jocit.2018.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
556 Senarathne W, Vranic S, Xiu J, Rose I, Gates P, Gatalica Z. Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. Annals of Diagnostic Pathology 2018;33:62-8. [DOI: 10.1016/j.anndiagpath.2017.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
557 Pulido M, Roubaud G, Cazeau AL, Mahammedi H, Vedrine L, Joly F, Mourey L, Pfister C, Goberna A, Lortal B, Bellera C, Pourquier P, Houédé N. Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. BMC Cancer 2018;18:194. [PMID: 29454321 DOI: 10.1186/s12885-018-4059-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
558 Shaver KA, Croom-Perez TJ, Copik AJ. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. Front Immunol 2021;12:679117. [PMID: 33995422 DOI: 10.3389/fimmu.2021.679117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
559 Choudhury N, Nakamura Y. Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci 2016;107:107-15. [PMID: 26678880 DOI: 10.1111/cas.12862] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
560 Xu P, Wang F, Guan C, Ouyang J, Shao X, Chen B. A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin. Onco Targets Ther 2016;9:5781-9. [PMID: 27703376 DOI: 10.2147/OTT.S112472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
561 Xu M, Han Y, Liu G, Xu Y, Duan D, Liu H, Du F, Luo P, Liu Z. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. Mol Pharm 2018;15:4426-33. [PMID: 30133286 DOI: 10.1021/acs.molpharmaceut.8b00371] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
562 Sengal A, Velazquez J, Hahne M, Burke TM, Abhyankar H, Reyes R, Olea W, Scull B, Eckstein OS, Bigenwald C, Bollard CM, Yu W, Merad M, McClain KL, Allen CE, Chakraborty R. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood 2021;137:1777-91. [PMID: 33075814 DOI: 10.1182/blood.2020005867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
563 Lee J, Ahn E, Kissick HT, Ahmed R. Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. For Immunopathol Dis Therap 2015;6:7-17. [PMID: 28286692 DOI: 10.1615/ForumImmunDisTher.2015014188] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
564 Schepisi G, Brighi N, Cursano MC, Gurioli G, Ravaglia G, Altavilla A, Burgio SL, Testoni S, Menna C, Farolfi A, Casadei C, Tonini G, Santini D, De Giorgi U. Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. J Oncol 2019;2019:7317964. [PMID: 31641355 DOI: 10.1155/2019/7317964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
565 Li X, Song W, Shao C, Shi Y, Han W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell Mol Immunol 2019;16:28-39. [PMID: 30002451 DOI: 10.1038/s41423-018-0086-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
566 Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 2017;28:2340-66. [PMID: 28945867 DOI: 10.1093/annonc/mdx310] [Cited by in Crossref: 233] [Cited by in F6Publishing: 212] [Article Influence: 58.3] [Reference Citation Analysis]
567 Muthigi A, George AK, Brancato SJ, Agarwal PK. Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. Ther Adv Urol 2016;8:203-14. [PMID: 27247630 DOI: 10.1177/1756287216628784] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
568 Jayaratna IS, Navai N, Dinney CP. Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Transl Androl Urol 2015;4:273-82. [PMID: 26816830 DOI: 10.3978/j.issn.2223-4683.2015.06.07] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
569 Yuan C, Liu Z, Yu Q, Wang X, Bian M, Yu Z, Yu J. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Sci Rep 2019;9:14356. [PMID: 31591439 DOI: 10.1038/s41598-019-50898-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
570 Kim ST, Klempner SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Lee J. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget. 2017;8:77415-77423. [PMID: 29100397 DOI: 10.18632/oncotarget.20492] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
571 Ghahremanloo A, Soltani A, Modaresi SMS, Hashemy SI. Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol (Dordr) 2019;42:609-26. [PMID: 31201647 DOI: 10.1007/s13402-019-00456-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
572 Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, Serre L, Jordheim LP, Matera EL, Dumontet C. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018;9:2100. [PMID: 30356816 DOI: 10.3389/fimmu.2018.02100] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
573 Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance. Methods Mol Biol 2018;1699:83-9. [PMID: 29086370 DOI: 10.1007/978-1-4939-7435-1_6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
574 Sankin A, Narasimhulu D, John P, Gartrell B, Schoenberg M, Zang X. The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. Urol Oncol 2018;36:459-68. [PMID: 28495553 DOI: 10.1016/j.urolonc.2017.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
575 Markel JE, Noore J, Emery EJ, Bobnar HJ, Kleinerman ES, Lindsey BA. Using the Spleen as an In Vivo Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with α-PD-L1. Sarcoma 2018;2018:8694397. [PMID: 30651716 DOI: 10.1155/2018/8694397] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
576 Mavratzas A, Seitz J, Smetanay K, Schneeweiss A, Jäger D, Fremd C. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncol 2020;16:4439-53. [PMID: 31829043 DOI: 10.2217/fon-2019-0468] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
577 Zeng T, Qin Q, Bian Z, Li J. Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). Artificial Cells, Nanomedicine, and Biotechnology 2019;47:4194-201. [DOI: 10.1080/21691401.2019.1687499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
578 Wang R, Zhang Y, Shan F. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer? Int Immunopharmacol 2021;103:108484. [PMID: 34954558 DOI: 10.1016/j.intimp.2021.108484] [Reference Citation Analysis]
579 Mardis E. Cancer Genomics. F1000Res 2015;4:F1000 Faculty Rev-1162. [PMID: 26937274 DOI: 10.12688/f1000research.6645.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
580 Hermans TJ, Fransen van de Putte EE, Horenblas S, Lemmens V, Aben K, van der Heijden MS, Beerepoot LV, Verhoeven RH, van Rhijn BW. Perioperative treatment and radical cystectomy for bladder cancer – a population based trend analysis of 10,338 patients in the Netherlands. European Journal of Cancer 2016;54:18-26. [DOI: 10.1016/j.ejca.2015.11.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
581 Alameddine M, Kineish O, Ritch C. Predicting Response to Intravesical Therapy in Non-muscle-invasive Bladder Cancer. Eur Urol Focus 2018;4:494-502. [PMID: 30098938 DOI: 10.1016/j.euf.2018.07.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
582 Mann JE, Hoesli R, Michmerhuizen NL, Devenport SN, Ludwig ML, Vandenberg TR, Matovina C, Jawad N, Mierzwa M, Shuman AG, Spector ME, Brenner JC. Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer 2017;8:332-44. [PMID: 28261333 DOI: 10.7150/jca.17547] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
583 Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
584 Fang W, Zhao S, Zhang Y, Ma Y, Zhao H, Zhang L. Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. Oncologist 2019;24:S11-20. [PMID: 30819827 DOI: 10.1634/theoncologist.2019-IO-S1-s03] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
585 Packiam VT, Pearce SM, Steinberg GD. The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancer. Ther Adv Urol 2016;8:29-37. [PMID: 26834838 DOI: 10.1177/1756287215607818] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
586 Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 2020;20:662-80. [PMID: 32753728 DOI: 10.1038/s41568-020-0285-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 132] [Article Influence: 61.0] [Reference Citation Analysis]
587 Liu X, Wu X, Cao S, Harrington SM, Yin P, Mansfield AS, Dong H. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. Sci Rep 2016;6:36722. [PMID: 27824138 DOI: 10.1038/srep36722] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
588 Komiya T, Madan R. PD-L1 expression in small cell lung cancer. European Journal of Cancer 2015;51:1853-5. [DOI: 10.1016/j.ejca.2015.06.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
589 Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL 3rd, Karrison T, Stadler WM, Nakamura Y, O'Donnell PH. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol 2016;34:2165-71. [PMID: 27044931 DOI: 10.1200/JCO.2015.66.3047] [Cited by in Crossref: 97] [Cited by in F6Publishing: 48] [Article Influence: 16.2] [Reference Citation Analysis]
590 Voorwerk L, Kat M, Kok M. Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Management 2018;7:BMT05. [DOI: 10.2217/bmt-2017-0014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
591 Kuş T, Aktaş G. Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival. Turk J Urol 2017;43:273-8. [PMID: 28861297 DOI: 10.5152/tud.2017.24478] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
592 Mori H, Kubo M, Yamaguchi R, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Oda Y, Nakamura M. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget 2017;8:15584-92. [PMID: 28107186 DOI: 10.18632/oncotarget.14698] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 11.6] [Reference Citation Analysis]
593 D'Arrigo P, Tufano M, Rea A, Vigorito V, Novizio N, Russo S, Romano MF, Romano S. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Curr Med Chem 2020;27:2402-48. [PMID: 30398102 DOI: 10.2174/0929867325666181106114421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
594 Zhan Y, Li Y, Guan B, Chen X, Chen Z, He A, He S, Gong Y, Peng D, Liu Y, Cai Z, Li X, Zhou L. Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma. Oncotarget 2017;8:44326-34. [PMID: 28574830 DOI: 10.18632/oncotarget.17872] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
595 Kitano Y, Yamashita YI, Nakao Y, Itoyama R, Yusa T, Umezaki N, Tsukamoto M, Yamao T, Miyata T, Nakagawa S, Okabe H, Imai K, Chikamoto A, Ishiko T, Baba H. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients. Ann Surg Oncol 2020;27:599-607. [PMID: 31407173 DOI: 10.1245/s10434-019-07701-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
596 Tang F, Zheng P. Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy? Cell Biosci 2018;8:34. [PMID: 29744030 DOI: 10.1186/s13578-018-0232-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
597 Lin X, Lu X, Luo G, Xiang H. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. Eur J Med Chem 2020;186:111876. [PMID: 31761384 DOI: 10.1016/j.ejmech.2019.111876] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
598 Li Y, Liang Z, Tian Y, Cai W, Weng Z, Chen L, Zhang H, Bao Y, Zheng H, Zeng S, Bei C, Li Y. High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2. Cancer Sci 2018;109:2435-45. [PMID: 29890018 DOI: 10.1111/cas.13666] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
599 Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Eur Urol Focus 2018;4:442-54. [PMID: 29056275 DOI: 10.1016/j.euf.2017.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
600 Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T. The New Era of Cancer Immunotherapy. Immunotherapy of Cancer. Elsevier; 2015. pp. 1-68. [DOI: 10.1016/bs.acr.2015.04.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
601 Lanzel EA, Paula Gomez Hernandez M, Bates AM, Treinen CN, Starman EE, Fischer CL, Parashar D, Guthmiller JM, Johnson GK, Abbasi T, Vali S, Brogden KA. Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. Cancer Immunol Immunother 2016;65:1511-22. [PMID: 27688163 DOI: 10.1007/s00262-016-1907-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
602 Walter D, Herrmann E, Schnitzbauer AA, Zeuzem S, Hansmann ML, Peveling-Oberhag J, Hartmann S. PD-L1 expression in extrahepatic cholangiocarcinoma. Histopathology 2017;71:383-92. [PMID: 28419539 DOI: 10.1111/his.13238] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
603 Moschini M, Dell'Oglio P, Luciano' R, Gandaglia G, Soria F, Mattei A, Klatte T, Damiano R, Shariat SF, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol 2017;35:335-41. [PMID: 28087131 DOI: 10.1016/j.urolonc.2016.12.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
604 Wu X, Ke X, Ni Y, Kuang L, Zhang F, Lin Y, Lin W, Xiong X, Huang H, Lin X, Zhang H. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma. J Immunol Res 2020;2020:8884683. [PMID: 33457428 DOI: 10.1155/2020/8884683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
605 Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R. Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci U S A 2018;115:4749-54. [PMID: 29654146 DOI: 10.1073/pnas.1718217115] [Cited by in Crossref: 139] [Cited by in F6Publishing: 133] [Article Influence: 34.8] [Reference Citation Analysis]
606 Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12:584-596. [PMID: 26122183 DOI: 10.1038/nrclinonc.2015.105] [Cited by in Crossref: 466] [Cited by in F6Publishing: 465] [Article Influence: 66.6] [Reference Citation Analysis]
607 Pfister C. [Urothelial tumors in 2016: Are we at the dawn of a new diagnostic and therapeutic era?]. Ann Pathol 2016;36:369-70. [PMID: 27912839 DOI: 10.1016/j.annpat.2016.11.001] [Reference Citation Analysis]
608 Perales MA, Sauter CS, Armand P. Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biol Blood Marrow Transplant 2016;22:17-22. [PMID: 26485445 DOI: 10.1016/j.bbmt.2015.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
609 Siu EH, Chan AW, Chong CC, Chan SL, Lo KW, Cheung ST. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Transl Gastroenterol Hepatol. 2018;3:89. [PMID: 30603725 DOI: 10.21037/tgh.2018.10.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
610 Cao W, Cheng W, Wu W. MicroRNAs Reprogram Tumor Immune Response. Methods Mol Biol 2018;1699:67-74. [PMID: 29086368 DOI: 10.1007/978-1-4939-7435-1_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
611 Kawashima A, Kanazawa T, Jingushi K, Kato T, Ujike T, Nagahara A, Fujita K, Morimoto-Okazawa A, Iwahori K, Uemura M, Imamura R, Wada H, Nonomura N. Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma. Clin Genitourin Cancer 2019;17:114-24. [PMID: 30555025 DOI: 10.1016/j.clgc.2018.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
612 Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res 2016;4:194-203. [PMID: 26787823 DOI: 10.1158/2326-6066.CIR-15-0210] [Cited by in Crossref: 204] [Cited by in F6Publishing: 122] [Article Influence: 34.0] [Reference Citation Analysis]
613 Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, Marone G, Tocchetti CG. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2017;2:e000247. [PMID: 29104763 DOI: 10.1136/esmoopen-2017-000247] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 19.6] [Reference Citation Analysis]
614 Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C. The clinical role of the TME in solid cancer. Br J Cancer 2019;120:45-53. [PMID: 30413828 DOI: 10.1038/s41416-018-0327-z] [Cited by in Crossref: 85] [Cited by in F6Publishing: 93] [Article Influence: 21.3] [Reference Citation Analysis]
615 Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH. Immunomodulation for glioblastoma. Curr Opin Neurol 2017;30:361-9. [PMID: 28368867 DOI: 10.1097/WCO.0000000000000451] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
616 Kim KJ, Yang HK, Kim WH, Kang GH. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget 2017;8:58887-902. [PMID: 28938605 DOI: 10.18632/oncotarget.19439] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
617 Li P, Hao S, Ye Y, Wei J, Tang Y, Tan L, Liao Z, Zhang M, Li J, Gui C, Xiao J, Huang Y, Chen X, Cao J, Luo J, Chen W. Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer. Front Cell Dev Biol 2021;9:646982. [PMID: 33816497 DOI: 10.3389/fcell.2021.646982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
618 Oike T, Sato H, Noda SE, Nakano T. Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University. Front Oncol 2016;6:139. [PMID: 27376029 DOI: 10.3389/fonc.2016.00139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
619 Hamilou Z, Lavaud P, Loriot Y. Atezolizumab in urothelial bladder carcinoma. Future Oncol 2018;14:331-41. [PMID: 29135284 DOI: 10.2217/fon-2017-0433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
620 Stühler V, Maas JM, Bochem J, da Costa IA, Todenhöfer T, Stenzl A, Bedke J. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. World J Urol 2019;37:1773-84. [PMID: 30374610 DOI: 10.1007/s00345-018-2538-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
621 Bangalore Kumar A, Maus R, Markovic SN. Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. Mayo Clinic Proceedings 2018;93:917-36. [DOI: 10.1016/j.mayocp.2018.03.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
622 Lin A, Qiu Z, Zhang J, Luo P. Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer. Front Immunol 2021;12:630773. [PMID: 33763074 DOI: 10.3389/fimmu.2021.630773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
623 Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res 2015;3:855-63. [PMID: 26014096 DOI: 10.1158/2326-6066.CIR-15-0024] [Cited by in Crossref: 50] [Cited by in F6Publishing: 23] [Article Influence: 7.1] [Reference Citation Analysis]
624 Teng F, Meng X, Kong L, Yu J. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. Cancer Lett 2018;414:166-73. [PMID: 29155348 DOI: 10.1016/j.canlet.2017.11.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 20.6] [Reference Citation Analysis]
625 Maruf M, Brancato SJ, Agarwal PK. Nonmuscle invasive bladder cancer: a primer on immunotherapy. Cancer Biol Med 2016;13:194-205. [PMID: 27458527 DOI: 10.20892/j.issn.2095-3941.2016.0020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
626 Yazdanpanah P, Alavianmehr A, Ghaderi A, Monabati A, Montazer M, Tahmasbi K, Farjadian S. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC. Breast Dis 2021;40:43-50. [PMID: 33523034 DOI: 10.3233/BD-201049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
627 Miyashita H, Mikami T, Satoi S, Cruz C, Galsky MD. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. Journal of Immunotherapy 2020;43:291-8. [DOI: 10.1097/cji.0000000000000339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
628 Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Büttner R. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. Pathologe 2016;37:557-67. [PMID: 27510417 DOI: 10.1007/s00292-016-0189-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
629 Chinn Z, Stoler MH, Mills AM. PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy. Histopathology 2019;74:256-68. [PMID: 30067880 DOI: 10.1111/his.13723] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
630 Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567. [PMID: 25428504 DOI: 10.1038/nature14011] [Cited by in Crossref: 2878] [Cited by in F6Publishing: 2815] [Article Influence: 411.1] [Reference Citation Analysis]
631 Mo Q, Li R, Adeegbe DO, Peng G, Chan KS. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Commun Biol 2020;3:784. [PMID: 33335285 DOI: 10.1038/s42003-020-01491-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
632 Kiselyov A, Bunimovich-Mendrazitsky S, Startsev V. Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment. Int J Cancer 2016;138:2562-9. [PMID: 26547270 DOI: 10.1002/ijc.29918] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
633 Roviello G, Catalano M, Nobili S, Santi R, Mini E, Nesi G. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? Int J Mol Sci 2020;21:E7935. [PMID: 33114616 DOI: 10.3390/ijms21217935] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
634 Zhang P, Liu Z, Wang D, Li Y, Xing Y, Xiao Y. Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer. Front Immunol 2021;12:724541. [PMID: 34512654 DOI: 10.3389/fimmu.2021.724541] [Reference Citation Analysis]
635 Wong JJW, Selbo PK. Light-controlled elimination of PD-L1+ cells. J Photochem Photobiol B 2021;225:112355. [PMID: 34768077 DOI: 10.1016/j.jphotobiol.2021.112355] [Reference Citation Analysis]
636 Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. Clin Genitourin Cancer 2018;16:e269-76. [PMID: 29199023 DOI: 10.1016/j.clgc.2017.10.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
637 Cho J, Ahn S, Yoo KH, Kim JH, Choi SH, Jang KT, Lee J. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Invest New Drugs 2016;34:677-84. [PMID: 27491654 DOI: 10.1007/s10637-016-0373-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
638 Khetrapal P, Tan WS, Lamb B, Nathan S, Briggs T, Shankar A, Ramachandran N, Freeman A, Mitra A, Kelly JD. Port-Site Metastases After Robotic Radical Cystectomy: A Systematic Review and Management Options. Clinical Genitourinary Cancer 2017;15:440-4. [DOI: 10.1016/j.clgc.2016.06.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
639 Chakrabarti R, Kapse B, Mukherjee G. Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. Cancer Rep (Hoboken) 2019;2:e1160. [PMID: 32721130 DOI: 10.1002/cnr2.1160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
640 Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pagès F. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol 2016;28:373-82. [PMID: 27121213 DOI: 10.1093/intimm/dxw021] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 15.5] [Reference Citation Analysis]
641 Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN). Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer 2016;4:15. [PMID: 26981245 DOI: 10.1186/s40425-016-0118-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
642 Verhoeff SR, van den Heuvel MM, van Herpen CM, Piet B, Aarntzen EH, Heskamp S. Programmed Cell Death-1/Ligand-1 PET Imaging. PET Clinics 2020;15:35-43. [DOI: 10.1016/j.cpet.2019.08.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
643 Vinay DS, Kwon BS. Harnessing immune checkpoints for cancer therapy. Immunotherapy 2018;10:1265-84. [PMID: 30326786 DOI: 10.2217/imt-2017-0168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
644 Bernard-Tessier A, Bonnet C, Lavaud P, Gizzi M, Loriot Y, Massard C. [Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma]. Bull Cancer 2018;105:140-5. [PMID: 29290331 DOI: 10.1016/j.bulcan.2017.10.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
645 Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol 2015;7:65-79. [PMID: 26000263 DOI: 10.2147/RRU.S63447] [Cited by in Crossref: 30] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
646 Jiang Y, Lo AWI, Wong A, Chen W, Wang Y, Lin L, Xu J. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Oncotarget 2017;8:30175-89. [PMID: 28404915 DOI: 10.18632/oncotarget.15621] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 12.5] [Reference Citation Analysis]
647 Inoue S, Kono M, Fukuda H, Shimamoto Y, Nakagawa K, Ohmori M, Iwagami H, Matsuno K, Iwatsubo T, Nakahira H, Matsuura N, Shichijo S, Maekawa A, Kanesaka T, Yamamoto S, Takeuchi Y, Higashino K, Uedo N, Kitamura M, Nakatsuka S, Kunimasa K, Kumagai T, Isei T, Ishihara R. Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitor-associated colitis. J Gastroenterol Hepatol 2021;36:1180-6. [PMID: 32888202 DOI: 10.1111/jgh.15246] [Reference Citation Analysis]
648 Ibrahim T, Gizzi M, Bahleda R, Loriot Y. Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer. BLC 2019;5:87-102. [DOI: 10.3233/blc-180205] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
649 Chovanec M, Cierna Z, Miskovska V, Machalekova K, Kalavska K, Rejlekova K, Svetlovska D, Macak D, Spanik S, Kajo K, Babal P, Mego M, Mardiak J. βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors. BMC Cancer 2018;18:1062. [PMID: 30390643 DOI: 10.1186/s12885-018-4929-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
650 Ding L, Lu S, Li Y. Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs. Pathol Oncol Res 2020;26:651-63. [PMID: 31748880 DOI: 10.1007/s12253-019-00735-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
651 Raimondi A, Randon G, Sepe P, Claps M, Verzoni E, de Braud F, Procopio G. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. Int J Mol Sci 2019;20:E4263. [PMID: 31480348 DOI: 10.3390/ijms20174263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
652 Salomon G, Maza A, Boulinguez S, Paul C, Lamant L, Tournier E, Mazereeuw-Hautier J, Meyer N. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. Br J Dermatol 2018;178:1199-203. [PMID: 29274233 DOI: 10.1111/bjd.16270] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
653 Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, Iglesia MD, Milowsky MI, Parker JS, Kim WY, Vincent BG. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight 2016;1:e85902. [PMID: 27699256 DOI: 10.1172/jci.insight.85902] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 17.2] [Reference Citation Analysis]
654 Prima V, Kaliberova LN, Kaliberov S, Curiel DT, Kusmartsev S. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc Natl Acad Sci U S A 2017;114:1117-22. [PMID: 28096371 DOI: 10.1073/pnas.1612920114] [Cited by in Crossref: 183] [Cited by in F6Publishing: 184] [Article Influence: 36.6] [Reference Citation Analysis]
655 Buchwald ZS, Efstathiou JA. Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer? Bladder Cancer 2015;1:15-27. [PMID: 30561443 DOI: 10.3233/BLC-150014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
656 Fearon DT. Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. Cold Spring Harb Symp Quant Biol 2016;81:219-26. [PMID: 28389597 DOI: 10.1101/sqb.2016.81.030783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
657 Suárez C, Puente J, Gallardo E, Méndez-Vidal MJ, Climent MA, León L, Olmos D, García del Muro X, González-Billalabeitia E, Grande E, Bellmunt J, Mellado B, Maroto P, González del Alba A. New advances in genitourinary cancer: evidence gathered in 2014. Cancer Metastasis Rev 2015;34:443-64. [PMID: 26227584 DOI: 10.1007/s10555-015-9577-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
658 Rose TL, Milowsky MI. Management of muscle-invasive bladder cancer in the elderly. Curr Opin Urol 2015;25:459-67. [PMID: 26075567 DOI: 10.1097/MOU.0000000000000190] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
659 Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41:868-876. [PMID: 26589760 DOI: 10.1016/j.ctrv.2015.11.001] [Cited by in Crossref: 228] [Cited by in F6Publishing: 230] [Article Influence: 32.6] [Reference Citation Analysis]
660 Lenis AT, Chamie K. Bladder cancer in 2014: From the genomic frontier to immunotherapeutics. Nat Rev Urol 2015;12:74-6. [PMID: 25558841 DOI: 10.1038/nrurol.2014.369] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
661 Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med 2021;218:e20201811. [PMID: 33974041 DOI: 10.1084/jem.20201811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
662 Ali HR, Glont SE, Blows FM, Provenzano E, Dawson SJ, Liu B, Hiller L, Dunn J, Poole CJ, Bowden S, Earl HM, Pharoah PD, Caldas C. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol 2015;26:1488-93. [PMID: 25897014 DOI: 10.1093/annonc/mdv192] [Cited by in Crossref: 146] [Cited by in F6Publishing: 153] [Article Influence: 20.9] [Reference Citation Analysis]
663 Erlmeier F, Seitz AK, Hatzichristodoulou G, Stecher L, Retz M, Gschwend JE, Weichert W, Kübler HR, Horn T. The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma. Bladder Cancer 2016;2:425-32. [PMID: 28035323 DOI: 10.3233/BLC-160067] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
664 Eftekhar SP, Yazdanpanah N, Rezaei N. Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. Expert Rev Anticancer Ther 2021;21:1211-28. [PMID: 34511008 DOI: 10.1080/14737140.2021.1979396] [Reference Citation Analysis]
665 Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, Nagano H, Nomura K, Okumura S, Shibutani T, Ishikawa Y. Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer 2017;103:44-51. [PMID: 28024695 DOI: 10.1016/j.lungcan.2016.11.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
666 Soria F, Beleni AI, D'Andrea D, Resch I, Gust KM, Gontero P, Shariat SF. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol. 2018;36:1703-1709. [PMID: 29549485 DOI: 10.1007/s00345-018-2264-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 10.5] [Reference Citation Analysis]
667 Yan Y, Zhang L, Zuo Y, Qian H, Liu C. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Arch Immunol Ther Exp 2020;68. [DOI: 10.1007/s00005-020-00601-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
668 Fakhrejahani F, Tomita Y, Maj-Hes A, Trepel JB, De Santis M, Apolo AB. Immunotherapies for bladder cancer: a new hope. Curr Opin Urol 2015;25:586-96. [PMID: 26372038 DOI: 10.1097/MOU.0000000000000213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
669 Ramos JD, Yu EY. Making urothelial carcinomas less immune to immunotherapy. Urol Oncol 2016;34:534-7. [PMID: 27836245 DOI: 10.1016/j.urolonc.2016.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
670 Willis BC, Sloan EA, Atkins KA, Stoler MH, Mills AM. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Mod Pathol 2017;30:1622-32. [PMID: 28752845 DOI: 10.1038/modpathol.2017.67] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
671 Weber JS. Biomarkers for Checkpoint Inhibition. Am Soc Clin Oncol Educ Book 2017;37:205-9. [PMID: 28561695 DOI: 10.1200/EDBK_175463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
672 Moschini M, Zamboni S, Mattei A, Amparore D, Fiori C, De Dominicis C, Esperto F; on behalf of the European Association of Urology - European Society of Resident Urologists (EAU-ESRU). Bacillus Calmette-Guérin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know. Minerva Urol Nefrol 2019;71. [DOI: 10.23736/s0393-2249.18.03309-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
673 Vincenzi B, Russo A, Terenzio A, Galvano A, Santini D, Vorini F, Antonelli-Incalzi R, Vespasiani-Gentilucci U, Tonini G. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol 2018;130:70-7. [PMID: 30196914 DOI: 10.1016/j.critrevonc.2018.06.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
674 Haanen JB, Blank CU. Prognostic and predictive role of the tumor immune landscape. Q J Nucl Med Mol Imaging 2020;64:143-51. [PMID: 32421286 DOI: 10.23736/S1824-4785.20.03255-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
675 Lee HS, Jang HJ, Choi JM, Zhang J, de Rosen VL, Wheeler TM, Lee JS, Tu T, Jindra PT, Kerman RH, Jung SY, Kheradmand F, Sugarbaker DJ, Burt BM. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight 2018;3:98575. [PMID: 29618661 DOI: 10.1172/jci.insight.98575] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
676 Inokuchi J, Eto M. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma. Cancer Manag Res 2019;11:4519-28. [PMID: 31191013 DOI: 10.2147/CMAR.S167708] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]